CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10705738,107057383,3,F,20141210,20150102,20150112,20220821,EXP,,UG-GLAXOSMITHKLINE-UG2014GSK046238,GLAXOSMITHKLINE,,37,YR,,M,Y,,,20220821,,MD,UG,UG,EFAVIRENZ,Blood bilirubin increased;Blood creatinine increased;Candida infection;Haemoptysis;Hepatotoxicity;Neutropenia;Pneumonia,107057383,DE,,,107057383,1,20141217,20141224,7,DAY,,,
12209859,122098592,2,F,20131001,20220826,20160325,20220908,EXP,,US-CIPLA LTD.-2016US02822,CIPLA,"Mikula JM, Manion MM, Maldarelli F, Suarez LM, Norman-Wheeler JF, Ober AG, et al.. Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir DF-associated renal tubulopathy. Antiviral Therapy. 2016;1 to 10",54,YR,,M,Y,,,20220908,,HP,US,US,EFAVIRENZ,Acute kidney injury;Drug resistance;Treatment failure,122098592,OT,,,122098592,1,2013,2014,,,122098592,1,HIV infection
12810571,128105715,5,F,,20220817,20161005,20220829,EXP,,CA-APOTEX-2016AP012493,APOTEX,,,,,M,Y,,,20220829,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,128105715,HO,,,,,,,,,128105715,1,Product used for unknown indication
12985056,129850569,9,F,,20220915,20161129,20220923,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52,YR,,M,Y,,,20220923,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,129850569,CA,,,,,,,,,129850569,1,HIV infection
13906408,1390640842,42,F,,20220920,20170825,20220927,EXP,,CA-009507513-0809CAN00001,MERCK,"Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22(14):1890-2",54,YR,,M,Y,,,20220927,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Diplopia;Drug interaction;Eyelid ptosis;Incorrect route of product administration;Intentional product use issue;Lipodystrophy acquired;Loss of personal independence in daily activities;Mitochondrial toxicity;Off label use;Paranoia;Prescribed overdose;Product use in unapproved indication;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation,1390640842,OT,,,1390640842,1,20070620,,,,1390640842,1,HIV infection
14221665,142216655,5,F,20170823,20220623,20171124,20220628,EXP,,PHHY2017CO172327,NOVARTIS,,57,YR,,M,Y,54,KG,20220628,,CN,CO,CO,EFAVIRENZ,Abdominal discomfort;Arthralgia;Decreased immune responsiveness;Inappropriate schedule of product administration;Malaise;Pain;Platelet count decreased;Somnolence,142216655,LT,,,142216655,1,20110317,,,,142216655,1,Chronic myeloid leukaemia
14248948,1424894811,11,F,,20220914,20171204,20220923,EXP,,GB-MYLANLABS-2017M1075159,MYLAN,,85,YR,,M,Y,,,20220923,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,1424894811,OT,,,1424894811,9,,,152,DAY,1424894811,1,Cardiovascular event prophylaxis
14306973,1430697313,13,F,,20220915,20171220,20220923,EXP,,CA-APOTEX-2017AP022582,APOTEX,,54,YR,,M,Y,,,20220923,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,1430697313,DE,,,,,,,,,1430697313,1,Bipolar disorder
15245128,152451283,3,F,20180209,20180731,20180806,20220713,EXP,,LS-GLAXOSMITHKLINE-LS2018GSK140125,GLAXOSMITHKLINE,,,,,,Y,,,20220713,,MD,LS,LS,EFAVIRENZ,Alanine aminotransferase increased;Altered state of consciousness;Aspartate aminotransferase increased;Dehydration;Dizziness;Feeling drunk;Gamma-glutamyltransferase increased;Hyperlactacidaemia;Hypokalaemia;Hypophagia;Hypotension;Hypothyroidism;Intestinal ischaemia;Metabolic acidosis;Oral herpes;Pneumocystis jirovecii pneumonia;Pulmonary embolism;Syncope;Tremor;Vomiting,152451283,HO,,,152451283,1,20180216,20180715,153,DAY,152451283,1,HIV infection
15357909,1535790931,31,F,20120521,20220928,20180906,20220929,EXP,,PHHY2018GB086977,NOVARTIS,,43,YR,,F,Y,,,20220929,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,1535790931,CA,,,1535790931,2,20100610,20180205,4,MON,1535790931,1,Product used for unknown indication
15361880,1536188017,17,F,20171006,20220907,20180907,20220908,EXP,,PHHY2018GB085930,NOVARTIS,,3,MON,,M,Y,,,20220908,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,1536188017,CA,,,1536188017,1,20171006,20180205,4,MON,1536188017,1,Foetal exposure during pregnancy
15370793,153707933,3,F,20171006,20220802,20180911,20220812,EXP,,GB-TEVA-2018-GB-953327,TEVA,,,,,M,Y,,,20220812,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Off label use;Trisomy 18;Ultrasound antenatal screen,153707933,DE,,,153707933,1,20171006,20180205,4,MON,153707933,1,HIV infection
15626751,1562675137,37,F,,20220818,20181116,20220819,EXP,,CA-ABBVIE-18S-028-2552613-00,ABBVIE,,54,YR,,M,Y,,,20220819,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1562675137,OT,,,,,,,,,1562675137,1,HIV infection
16020890,1602089022,22,F,,20220628,20190301,20220712,EXP,,CA-AUROBINDO-AUR-APL-2019-010743,AUROBINDO,,54,YR,,M,Y,,,20220712,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,1602089022,DE,,,,,,,,,1602089022,1,HIV infection
16338358,163383584,4,F,20131001,20220714,20190521,20220719,PER,,US-GILEAD-2019-0408525,GILEAD,,45,YR,A,M,Y,,,20220719,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Drug ineffective;Economic problem;Emotional distress;Pain,163383584,OT,,,163383584,1,201208,201807,,,163383584,1,HIV infection
16430786,164307866,6,F,20050101,20220718,20190614,20220719,EXP,,US-GILEAD-2019-0413028,GILEAD,,,,A,M,Y,74.83,KG,20220719,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Osteonecrosis;Pain;Post-traumatic stress disorder;Renal cyst;Tooth loss,164307866,OT,,,164307866,1,2010,201701,,,164307866,1,HIV infection
16507857,165078573,3,F,20020101,20190624,20190701,20220713,EXP,,DE-GLAXOSMITHKLINE-DE2019GSK116835,GLAXOSMITHKLINE,,,,,,Y,,,20220713,,MD,DE,DE,EFAVIRENZ;SUSTIVA,Aortic stenosis;Arthralgia;Asthenia;Bronchial carcinoma;Chest pain;Coronary artery disease;Dysphagia;Dyspnoea;Haematuria;Myopathy;Papillary renal cell carcinoma;Stenosis;Systemic scleroderma;Weight decreased,165078573,HO,,,165078573,1,199702,201510,,,165078573,1,HIV infection
17044956,1704495610,10,F,,20220926,20191118,20220928,EXP,,CA-BAUSCH-BL-2019-058588,BAUSCH AND LOMB,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1892. doi:10.1097/QAD.0b013e32830e0169",54,YR,,M,Y,,,20220928,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1704495610,OT,,,,,,,,,1704495610,1,Bipolar disorder
17291318,172913186,6,F,20120209,20220831,20200121,20220907,EXP,,US-GILEAD-2020-0447102,GILEAD,,40,YR,A,M,Y,104.31,KG,20220907,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Dental caries;Economic problem;Emotional distress;Exercise tolerance decreased;Fatigue;Fracture;Multiple fractures;Osteonecrosis;Pain;Quality of life decreased;Renal cyst;Renal failure;Renal impairment;Tooth loss,172913186,OT,,,172913186,1,201111,2013,2,DAY,172913186,1,HIV infection
17549495,175494955,5,F,,20200801,20200317,20220713,EXP,,NG-GLAXOSMITHKLINE-NG2020GSK046275,GLAXOSMITHKLINE,,,,,,Y,,,20220713,,HP,NG,NG,EFAVIRENZ,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,175494955,CA,,,,,,,,,175494955,1,HIV infection
17551291,175512912,2,F,20090619,20220329,20200317,20220823,EXP,,FR-MYLANLABS-2019M1038547,MYLAN,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).. Chemical biology + drug design. 2018",42,YR,,F,Y,,,20220823,,HP,FR,FR,EFAVIRENZ,Drug resistance;Viral mutation identified,175512912,OT,,,,,,,,,175512912,1,HIV infection
17570438,175704384,4,F,20110101,20220708,20200323,20220714,EXP,,US-GILEAD-2020-0455808,GILEAD,,69,YR,E,M,Y,74,KG,20220714,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Economic problem;Emotional distress;Fracture;Hip fracture;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Tooth loss,175704384,OT,,,175704384,1,200701,201907,1360,DAY,175704384,1,HIV infection
17697238,176972383,3,F,,20200806,20200423,20220713,EXP,,JP-GLAXOSMITHKLINE-JP2020068351,GLAXOSMITHKLINE,,,,,,Y,,,20220713,,MD,JP,JP,EFAVIRENZ,Surgical vascular shunt,176972383,HO,,,,,,,,,,,
17917665,179176656,6,F,20100920,20220707,20200619,20220817,EXP,,US-GILEAD-2020-0473759,GILEAD,,59,YR,A,M,Y,76.19,KG,20220817,,LW,US,US,SUSTIVA,Acute kidney injury;Bone density decreased;End stage renal disease;Fatigue;General physical health deterioration;Libido decreased;Medical diet;Nephrogenic anaemia;Nephropathy;Osteoporosis;Renal failure,179176656,HO,,,179176656,1,20031206,20040407,123,DAY,179176656,1,HIV infection
17949727,1794972716,16,F,,20220914,20200626,20220923,EXP,CA-MHPD-E2B_02966351,CA-Accord-186554,ACCORD,,54,YR,A,M,Y,,,20220923,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,1794972716,DE,,,,,,,,,1794972716,1,Bipolar disorder
17989419,179894193,3,F,20050101,20220728,20200707,20220805,EXP,,US-GILEAD-2020-0478431,GILEAD,,,,A,M,Y,92.986,KG,20220805,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Chronic kidney disease;Depression;Dysstasia;Emotional distress;Gait disturbance;Lower limb fracture;Osteopenia;Pain;Renal failure;Renal impairment;Tooth loss,179894193,OT,,,179894193,1,200401,201001,,,179894193,1,HIV infection
17990876,1799087624,24,F,,20220919,20200707,20220926,EXP,,GB-MYLANLABS-2020M1060756,MYLAN,,,,,M,Y,,,20220926,,CN,GB,GB,EFAVIRENZ,Feeling abnormal;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1799087624,HO,,,,,,,,,1799087624,1,Product used for unknown indication
18002318,1800231820,20,F,,20220817,20200709,20220830,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-053886,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20220830,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1800231820,OT,,,,,,,,,1800231820,1,Product used for unknown indication
18022611,1802261124,24,F,,20220904,20200715,20220915,EXP,,GB-AUROBINDO-AUR-APL-2020-034425,AUROBINDO,,,,,M,Y,,,20220915,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1802261124,OT,,,,,,,,,1802261124,1,Product used for unknown indication
18043574,180435746,6,F,20100801,20220719,20200720,20220722,EXP,,US-GILEAD-2020-0483861,GILEAD,,59,YR,A,M,Y,175,KG,20220722,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Bone pain;Dysstasia;Emotional distress;Gait disturbance;Osteoporosis;Pain;Pollakiuria;Renal failure;Renal impairment;Tooth loss,180435746,OT,,,180435746,1,200708,2018,,,180435746,1,HIV infection
18065589,180655894,4,F,,20220829,20200724,20220912,EXP,CA-MHPD-E2B_02992182,CA-Accord-191476,ACCORD,,44,YR,A,M,Y,,,20220912,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,180655894,HO,,,180655894,13,,,365,DAY,180655894,1,Depression
18705278,187052784,4,F,20090326,20220824,20210106,20220826,EXP,,US-GILEAD-2021-0511357,GILEAD,,34,YR,A,M,Y,78.93,KG,20220826,,LW,US,US,SUSTIVA,"Acute kidney injury;Anxiety;Asthenia;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Clavicle fracture;Decreased appetite;Delusional disorder, unspecified type;Depression;Dysstasia;End stage renal disease;Fatigue;Fracture;Micturition disorder;Mobility decreased;Multiple fractures;Muscle spasms;Nausea;Night sweats;Renal failure;Tooth loss",187052784,HO,,,187052784,1,2004,2013,1855,DAY,187052784,1,HIV infection
18739841,187398412,2,F,20050401,20210108,20210114,20220714,EXP,,JP-GLAXOSMITHKLINE-JP2021JPN003775,GLAXOSMITHKLINE,,,,,,Y,,,20220714,,MD,JP,JP,EFAVIRENZ,Blood lactate dehydrogenase increased;Diabetes mellitus;Dyslipidaemia;Renal impairment,187398412,OT,,,187398412,1,201302,,,,187398412,1,HIV infection
18867829,188678293,3,F,,20210211,20210209,20220713,EXP,,FR-GLAXOSMITHKLINE-FR2021GSK033741,GLAXOSMITHKLINE,,,,,,Y,,,20220713,,HP,FR,FR,EFAVIRENZ,Foetal exposure during pregnancy;Polycystic liver disease;Sickle cell disease;Spleen malformation,188678293,CA,,,188678293,1,20060426,20061018,130,DAY,188678293,1,HIV infection
18920769,189207693,3,F,20140101,20220802,20210222,20220804,PER,,"US-REGENERON PHARMACEUTICALS, INC.-2021-20931",REGENERON,,,,,F,Y,,,20220804,,CN,US,US,EFAVIRENZ,Fatigue;Headache;Hypothyroidism;Muscle spasms;Plasma cell myeloma;Vascular occlusion,189207693,OT,,,189207693,1,2014,,,,189207693,1,Hypercholesterolaemia
19022359,190223594,4,F,,20220712,20210318,20220714,EXP,,DE-009507513-2103DEU001244,MERCK,,57,YR,,M,Y,,,20220714,,MD,DE,DE,EFAVIRENZ,Drug resistance,190223594,OT,,,,,,,,,190223594,1,HIV infection
19117314,191173143,3,F,20201014,20220807,20210409,20220809,EXP,,CN-GILEAD-2021-0521065,GILEAD,,,,A,M,Y,50,KG,20220809,,HP,CN,CN,EFAVIRENZ,Insomnia,191173143,DS,,,191173143,1,20200919,20201214,86,DAY,191173143,1,HIV infection
19603988,196039882,2,F,,20220831,20210723,20220906,EXP,,CA-AstraZeneca-2021A627254,ASTRAZENECA,,54,YR,,M,Y,,,20220906,,MD,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,196039882,DE,,,,,,,,,196039882,1,Bipolar disorder
19689296,196892962,2,F,,20220817,20210812,20220824,EXP,,CA-APOTEX-2021AP029841,APOTEX,,54,YR,,M,Y,,,20220824,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196892962,OT,,,,,,,,,196892962,1,Bipolar disorder
19711338,197113385,5,F,,20220711,20210817,20220715,EXP,,DE-MYLANLABS-2021M1052063,MYLAN,,57,YR,,M,Y,,,20220715,,MD,DE,DE,EFAVIRENZ,Drug resistance,197113385,OT,,,,,,,,,197113385,1,HIV infection
19714509,197145097,7,F,,20220831,20210818,20220906,EXP,,CA-JNJFOC-20210821624,JOHNSON AND JOHNSON,,40,YR,A,F,Y,,,20220906,,HP,CA,CA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Bacillus infection;Bacterial vulvovaginitis;Cataract;Cellulitis;Central obesity;Colitis ulcerative;Cushingoid;Drug ineffective;Escherichia infection;Furuncle;Therapy non-responder;Weight increased,197145097,OT,,,197145097,1,,,7,MON,197145097,1,Colitis ulcerative
19803160,198031602,2,F,,20220704,20210908,20220708,EXP,,JP-GLAXOSMITHKLINE-JP2021JPN188941,GLAXOSMITHKLINE,"Nakamura H, Miyazaki N, Hosoya N, Koga M, Odawara T, Kikuchi T, et al.. Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir. Japanese Society of Chemotherapy and The Japanese Association for Infectious Dis. 2010;17:105-110",,,,,Y,,,20220708,,MD,JP,JP,EFAVIRENZ,Blood HIV RNA increased;Pathogen resistance;Rash;Viraemia,198031602,OT,,,,,,,,,198031602,1,HIV infection
19803165,198031652,2,F,,20220704,20210908,20220708,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN188941,VIIV,"Nakamura H, Miyazaki N, Hosoya N, Koga M, Odawara T, Kikuchi T, et al.. Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir. Japanese Society of Chemotherapy and The Japanese Association for Infectious Dis. 2010;17:105-110",,,,,Y,,,20220708,,MD,JP,JP,EFAVIRENZ,Blood HIV RNA increased;Pathogen resistance;Rash;Viraemia,198031652,OT,,,,,,,,,198031652,1,HIV infection
19895117,198951172,2,F,,20210927,20210929,20220714,EXP,,JP-GLAXOSMITHKLINE-JP2021JPN202612,GLAXOSMITHKLINE,,,,,,Y,,,20220714,,MD,JP,JP,EFAVIRENZ,Diarrhoea;Renal cancer;Renal impairment,198951172,OT,,,,,,,,,198951172,1,HIV infection
19934204,199342042,2,F,,20220922,20211008,20220927,EXP,,CA-MYLANLABS-2021M1071033,MYLAN,,54,YR,,M,Y,,,20220927,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,199342042,OT,,,,,,,,,199342042,1,Bipolar disorder
19938893,1993889319,19,F,,20220826,20211011,20220906,EXP,,CA-MYLANLABS-11P-028-0710272-00,MYLAN,,54,YR,,M,Y,,,20220906,,CN,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,1993889319,DE,,,,,,,,,1993889319,1,Bipolar disorder
19939208,199392083,3,F,,20220922,20211011,20220927,EXP,,CA-MYLANLABS-2021M1071030,MYLAN,,54,YR,,M,Y,,,20220927,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,199392083,OT,,,,,,,,,199392083,1,Bipolar disorder
20041003,200410033,3,F,20070901,20220809,20211107,20220815,EXP,,US-GILEAD-2021-0555190,GILEAD,,42,YR,A,M,Y,81.633,KG,20220815,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Emotional distress;Fatigue;Osteoporosis;Pain;Protein urine present;Renal failure;Renal impairment,200410033,HO,,,200410033,1,2006,2018,,,200410033,1,HIV infection
20057137,200571374,4,F,20020605,20220907,20211111,20220909,EXP,,JP-GLAXOSMITHKLINE-A20032850,GLAXOSMITHKLINE,,,,,,Y,,,20220909,,MD,JP,JP,EFAVIRENZ,Blood uric acid increased;Cataract;Gastrooesophageal reflux disease;Hyperlipidaemia;Hypertension;Hyperuricaemia;Lipoatrophy;Otitis media,200571374,HO,,,200571374,1,20010627,20030331,642,DAY,200571374,1,Acquired immunodeficiency syndrome
20057140,200571404,4,F,20020605,20220907,20211111,20220909,EXP,,JP-VIIV HEALTHCARE LIMITED-A20032850,VIIV,,,,,,Y,,,20220909,,MD,JP,JP,EFAVIRENZ,Blood uric acid increased;Cataract;Gastrooesophageal reflux disease;Hyperlipidaemia;Hypertension;Hyperuricaemia;Lipoatrophy;Otitis media,200571404,HO,,,200571404,1,20010627,20030331,642,DAY,200571404,1,Acquired immunodeficiency syndrome
20089476,200894762,2,F,20030101,20220629,20211119,20220705,EXP,,DE-ABBVIE-21K-062-4165446-00,ABBVIE,,,,A,M,Y,,,20220705,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,200894762,OT,,,200894762,1,1997,,,,200894762,1,HIV infection
20095219,200952192,2,F,20080101,20220629,20211122,20220704,EXP,,DE-ABBVIE-21K-062-4165442-00,ABBVIE,,,,A,M,Y,,,20220704,,CN,DE,DE,EFAVIRENZ,Pathogen resistance,200952192,OT,,,200952192,1,1997,,,,200952192,1,HIV infection
20150086,201500863,3,F,20150101,20220629,20211206,20220704,EXP,,US-GILEAD-2021-0557126,GILEAD,,55,YR,A,M,Y,79.37,KG,20220704,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone pain;Chronic kidney disease;Depression;Emotional distress;Insomnia;Osteopenia;Pain;Patella fracture;Pneumonia;Pollakiuria;Renal failure;Renal injury;Urinary tract infection;Weight increased,201500863,HO,,,201500863,1,2015,2017,,,201500863,1,HIV infection
20170766,201707662,2,F,20130901,20220713,20211210,20220721,EXP,,US-GILEAD-2021-0557388,GILEAD,,51,YR,A,M,Y,68.934,KG,20220721,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Pain;Renal impairment,201707662,OT,,,201707662,1,201212,201310,,,201707662,1,HIV infection
20224278,202242784,4,F,20080701,20220827,20211223,20220831,PER,,US-GILEAD-2021-0561994,GILEAD,,63,YR,A,F,Y,70.295,KG,20220831,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Drug interaction;Emotional distress;Fall;Foot fracture;Hand fracture;Humerus fracture;Joint contracture;Limb immobilisation;Loss of personal independence in daily activities;Lower limb fracture;Neuralgia;Osteoporosis;Pain;Pain in extremity;Skeletal injury;Spinal osteoarthritis;Tibia fracture;Upper limb fracture,202242784,OT,,,202242784,1,2005,201401,,,202242784,1,HIV infection
20230602,202306022,2,F,20161201,20220810,20211227,20220815,EXP,,US-GILEAD-2021-0562338,GILEAD,,51,YR,A,M,Y,115.19,KG,20220815,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Back pain;Chronic kidney disease;Emotional distress;Gait disturbance;Oedema peripheral;Pain;Pollakiuria;Renal injury,202306022,OT,,,202306022,1,2001,2016,,,202306022,1,HIV infection
20230921,202309212,2,F,20171101,20220831,20211227,20220902,EXP,,US-GILEAD-2021-0562335,GILEAD,,55,YR,A,M,Y,86.168,KG,20220902,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone loss;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Metabolic acidosis;Osteomalacia;Pain;Renal injury,202309212,OT,,,202309212,1,200509,201801,,,202309212,1,HIV infection
20299652,202996522,2,F,20150501,20220803,20220105,20220808,PER,,US-GILEAD-2022-0563898,GILEAD,,62,YR,A,M,Y,82.086,KG,20220807,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone pain;Emotional distress;Mobility decreased;Osteopenia;Pain;Renal impairment;Upper limb fracture,202996522,OT,,,202996522,1,2006,201602,,,202996522,1,HIV infection
20302666,203026663,3,F,20170201,20220802,20220106,20220804,PER,,US-GILEAD-2022-0563849,GILEAD,,64,YR,A,F,Y,48.98,KG,20220804,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Asthenia;Back pain;Chronic kidney disease;Emotional distress;Fatigue;Hypokalaemia;Memory impairment;Pain;Renal failure;Renal pain;Renal tubular necrosis,203026663,HO,,,203026663,1,2016,20170119,126,DAY,203026663,1,HIV infection
20303504,203035042,2,F,20150101,20220818,20220106,20220822,EXP,,US-GILEAD-2022-0563909,GILEAD,,60,YR,A,F,Y,247,KG,20220822,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Balance disorder;Chronic kidney disease;Cognitive disorder;Depression;Emotional distress;Hyperparathyroidism;Pain;Renal injury;Skeletal injury,203035042,OT,,,203035042,1,2006,2013,,,203035042,1,HIV infection
20304292,203042922,2,F,20100101,20220825,20220106,20220830,PER,,US-GILEAD-2022-0563855,GILEAD,,,,A,M,Y,122.45,KG,20220830,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Depression;Emotional distress;Hand fracture;Osteopenia;Pain;Tooth loss;Wrist fracture,,,,,203042922,1,2012,,,,203042922,1,HIV infection
20305983,203059832,2,F,20160101,20220803,20220106,20220808,EXP,,US-GILEAD-2022-0563902,GILEAD,,,,A,M,Y,65.306,KG,20220808,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Chronic kidney disease;Emotional distress;Foot fracture;General physical health deterioration;Hypertension;Ill-defined disorder;Neck injury;Osteoporosis;Pain;Renal failure,203059832,OT,,,203059832,1,2004,201705,,,203059832,1,HIV infection
20306354,203063542,2,F,20141101,20220920,20220106,20220923,EXP,,US-GILEAD-2022-0563785,GILEAD,,39,YR,A,M,Y,77.551,KG,20220923,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Asthenia;Back pain;Bone demineralisation;Chronic kidney disease;Condition aggravated;Dysstasia;Emotional distress;Exercise tolerance decreased;Fatigue;Gait disturbance;Insomnia;Osteopenia;Pain;Pollakiuria;Renal pain,203063542,OT,,,203063542,1,2004,201703,,,203063542,1,HIV infection
20306374,203063742,2,F,20181101,20220803,20220106,20220805,EXP,,US-GILEAD-2022-0563771,GILEAD,,64,YR,A,M,Y,90.703,KG,20220805,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Enzyme level increased;Pain;Renal disorder;Renal injury,203063742,OT,,,203063742,1,2006,201812,,,203063742,1,HIV infection
20349666,203496663,3,F,20160201,20220815,20220119,20220817,PER,,US-GILEAD-2022-0565660,GILEAD,,45,YR,A,F,Y,102.04,KG,20220817,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone demineralisation;Decreased activity;Depression;Emotional distress;Fear of falling;Osteoarthritis;Osteopenia;Osteoporosis;Pain,203496663,OT,,,203496663,1,2005,201003,,,203496663,1,HIV infection
20351646,203516462,2,F,20060101,20220701,20220119,20220705,EXP,,US-GILEAD-2022-0565657,GILEAD,,,,A,F,Y,74.376,KG,20220705,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Cardiac disorder;Chronic kidney disease;Degenerative bone disease;Emotional distress;Exercise tolerance decreased;Gait disturbance;Insomnia;Lipodystrophy acquired;Loss of personal independence in daily activities;Nephrolithiasis;Osteopenia;Pain;Pain in extremity;Urinary tract infection,203516462,HO,,,203516462,1,2001,2008,,,203516462,1,HIV infection
20354006,203540062,2,F,20140101,20220803,20220120,20220225,EXP,,US-GILEAD-2022-0565984,GILEAD,,,,A,M,Y,92.063,KG,20220808,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Foot fracture;Gait disturbance;Osteoporosis;Pain;Rib fracture,203540062,OT,,,203540062,1,200803,201609,,,203540062,1,HIV infection
20355563,203555632,2,F,20170601,20220925,20220120,20220927,EXP,,US-GILEAD-2022-0565913,GILEAD,,66,YR,E,M,Y,71.21,KG,20220927,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone demineralisation;Emotional distress;Osteoporosis;Pain,203555632,OT,,,203555632,1,2006,2018,,,203555632,1,HIV infection
20357937,203579373,3,F,20110601,20220808,20220120,20220812,PER,,US-GILEAD-2022-0565950,GILEAD,,45,YR,A,M,Y,54.422,KG,20220811,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone demineralisation;Depression;Drug resistance;Emotional distress;General physical health deterioration;Hand fracture;Osteopenia;Osteoporosis;Pain,203579373,OT,,,203579373,1,2006,201405,,,203579373,1,HIV infection
20364389,203643894,4,F,20150901,20220719,20220121,20220722,EXP,,US-GILEAD-2022-0565663,GILEAD,,52,YR,A,M,Y,104.31,KG,20220722,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Pain;Renal impairment,203643894,OT,,,203643894,1,2011,201609,,,203643894,1,HIV infection
20365717,203657172,2,F,20120101,20220925,20220123,20220928,PER,,US-GILEAD-2022-0565891,GILEAD,,,,A,F,Y,92.517,KG,20220928,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back injury;Back pain;Bone demineralisation;Bone density decreased;Chondropathy;Collagen disorder;Depression;Dysstasia;Emotional distress;Gait disturbance;Pain;Therapeutic response decreased,,,,,203657172,1,2004,2012,,,203657172,1,HIV infection
20367792,203677922,2,F,20030101,20220902,20220124,20220908,EXP,,US-GILEAD-2022-0565861,GILEAD,,,,A,M,Y,77.098,KG,20220908,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Blood glucose increased;Chronic kidney disease;Diabetes mellitus;Emotional distress;Glomerular filtration rate decreased;Pain;Protein urine present;Renal failure;Renal injury,203677922,OT,,,203677922,1,2001,2004,,,203677922,1,HIV infection
20371223,203712232,2,F,20150301,20220823,20220124,20220826,EXP,,US-GILEAD-2022-0566467,GILEAD,,50,YR,A,F,Y,73.016,KG,20220826,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Depression;Emotional distress;Foot fracture;Gait disturbance;Multiple fractures;Osteoporosis;Pain;Pain in extremity;Proteinuria;Renal injury,203712232,OT,,,203712232,1,2005,201906,,,203712232,1,HIV infection
20372264,203722642,2,F,20160101,20220824,20220124,20220829,EXP,,US-GILEAD-2022-0566378,GILEAD,,,,A,F,Y,50.794,KG,20220829,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Bone demineralisation;Dysstasia;Emotional distress;Fall;Gait disturbance;Hand fracture;Multiple fractures;Musculoskeletal stiffness;Osteoporosis;Pain;Rib fracture,203722642,OT,,,203722642,1,2008,2018,,,203722642,1,HIV infection
20448026,204480262,2,F,20120701,20220711,20220209,20220715,EXP,,US-GILEAD-2022-0569042,GILEAD,,56,YR,A,M,Y,81.647,KG,20220715,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Emotional distress;Fatigue;Osteoporosis;Pain,204480262,OT,,,204480262,1,2002,201302,,,204480262,1,HIV infection
20449993,204499932,2,F,20141201,20220925,20220209,20220930,EXP,,US-GILEAD-2022-0569076,GILEAD,,54,YR,A,M,Y,96.599,KG,20220930,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Body height decreased;Emotional distress;Gait disturbance;General physical health deterioration;Multiple fractures;Osteopenia;Osteoporosis;Pain;Rib fracture;Spinal compression fracture;Upper limb fracture,204499932,OT,,,204499932,1,2003,2004,,,204499932,1,HIV infection
20451718,204517182,2,F,20120101,20220831,20220209,20220906,EXP,,US-GILEAD-2022-0569265,GILEAD,,,,A,F,Y,108.84,KG,20220906,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Bone demineralisation;Depression;Emotional distress;Foot fracture;Gait disturbance;Insomnia;Malaise;Nausea;Osteoporosis;Pain,204517182,OT,,,204517182,1,2001,2003,,,204517182,1,HIV infection
20454381,204543812,2,F,20140101,20220816,20220210,20220822,EXP,,US-GILEAD-2022-0569129,GILEAD,,,,E,M,Y,63.5,KG,20220822,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;Muscle atrophy;Pain,204543812,OT,,,204543812,1,2014,201509,,,204543812,1,HIV infection
20456732,204567323,3,F,20110701,20220901,20220210,20220908,PER,,US-GILEAD-2022-0569157,GILEAD,,53,YR,A,F,Y,107,KG,20220908,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Chronic kidney disease;Colitis;Depression;Emotional distress;Gait disturbance;Insomnia;Intervertebral disc degeneration;Nocturia;Osteopenia;Pain;Pollakiuria;Product dose omission issue;Renal failure;Renal impairment;Renal injury,204567323,OT,,,204567323,1,2004,201107,,,204567323,1,HIV infection
20456758,204567582,2,F,20150101,20220816,20220210,20220822,EXP,,US-GILEAD-2022-0569475,GILEAD,,,,A,F,Y,108.84,KG,20220821,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Emotional distress;Mobility decreased;Osteoporosis;Pain;Skeletal injury,204567582,OT,,,204567582,1,2006,201608,,,204567582,1,HIV infection
20472918,204729183,3,F,20160101,20220802,20220215,20220805,PER,,US-GILEAD-2022-0569202,GILEAD,,,,A,M,Y,73.469,KG,20220805,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Emotional distress;General physical health deterioration;Glomerular filtration rate abnormal;Haematuria;Hypertension;Muscle spasms;Pain;Renal impairment;Renal injury,204729183,OT,,,204729183,1,2004,201708,,,204729183,1,HIV infection
20472920,204729202,2,F,20160101,20220802,20220215,20220805,PER,,US-GILEAD-2022-0569537,GILEAD,,,,A,M,Y,79.378,KG,20220804,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Gait disturbance;Haematuria;Hypotension;Mobility decreased;Pain;Renal impairment;Urinary tract disorder,204729202,OT,,,204729202,1,2006,2018,,,204729202,1,HIV infection
20476575,204765752,2,F,20180701,20220629,20220215,20220704,PER,,US-GILEAD-2022-0569162,GILEAD,,54,YR,A,M,Y,,,20220704,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Decreased activity;Emotional distress;Gait disturbance;Hypoaesthesia;Mobility decreased;Osteopenia;Pain;Pain in extremity;Self esteem decreased;Skeletal injury;Weight increased,,,,,204765752,1,2011,2018,,,204765752,1,HIV infection
20478539,204785392,2,F,20170101,20220802,20220216,20220804,PER,,US-GILEAD-2022-0569044,GILEAD,,,,A,M,Y,59.41,KG,20220804,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bone demineralisation;Bone density decreased;Cardiac disorder;Dehydration;Emotional distress;Foot fracture;Gait disturbance;Loss of personal independence in daily activities;Musculoskeletal disorder;Pain;Renal disorder,,,,,204785392,1,2005,201807,,,204785392,1,HIV infection
20479188,204791883,3,F,20110101,20220809,20220216,20220816,EXP,,US-GILEAD-2022-0569062,GILEAD,,51,YR,A,M,Y,72.562,KG,20220816,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Blood creatinine increased;Bone pain;Contusion;Depression;Emotional distress;Exercise tolerance decreased;Fatigue;Hand fracture;Hydronephrosis;Osteopenia;Pain;Renal failure;Renal impairment;Skull fracture,204791883,OT,,,204791883,1,2004,2015,,,204791883,1,HIV infection
20479484,204794842,2,F,20090101,20220803,20220216,20220804,PER,,US-GILEAD-2022-0569130,GILEAD,,,,A,M,Y,78.458,KG,20220804,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Dysstasia;Emotional distress;Fractured coccyx;Impaired driving ability;Orthostatic hypotension;Osteopenia;Pain;Tinnitus;Tooth loss;Upper limb fracture,,,,,204794842,1,2006,201802,,,204794842,1,HIV infection
20479608,204796082,2,F,20190101,20220715,20220216,20220720,PER,,US-GILEAD-2022-0569302,GILEAD,,,,A,M,Y,325,KG,20220719,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain;Proteinuria;Renal impairment,204796082,OT,,,204796082,1,2007,2019,,,204796082,1,HIV infection
20481671,204816712,2,F,20170101,20220816,20220216,20220817,PER,,US-GILEAD-2022-0569116,GILEAD,,,,A,M,Y,185,KG,20220817,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Balance disorder;Bone density decreased;Emotional distress;Gait disturbance;Osteopenia;Pain;Tooth loss,,,,,204816712,1,2011,2017,,,204816712,1,HIV infection
20481696,204816962,2,F,20160101,20220912,20220216,20220919,PER,,US-GILEAD-2022-0569327,GILEAD,,70,YR,E,M,Y,93.878,KG,20220919,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Laboratory test abnormal;Pain;Renal impairment,204816962,OT,,,204816962,1,2004,2016,,,204816962,1,HIV infection
20484656,204846562,2,F,20170101,20220902,20220217,20220904,PER,,US-GILEAD-2022-0569088,GILEAD,,,,A,M,Y,77.098,KG,20220904,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Emotional distress;General physical health deterioration;Osteopenia;Pain,,,,,204846562,1,2005,2016,,,204846562,1,HIV infection
20486717,204867172,2,F,20160101,20220906,20220217,20220908,PER,,US-GILEAD-2022-0569381,GILEAD,,,,A,F,Y,79.819,KG,20220908,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Osteopenia;Pain;Quality of life decreased,,,,,204867172,1,2007,201707,,,204867172,1,HIV infection
20491985,204919852,2,F,20090101,20220729,20220218,20220801,PER,,US-GILEAD-2022-0569392,GILEAD,,,,A,M,Y,83.915,KG,20220801,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Dysstasia;Emotional distress;Muscle spasms;Musculoskeletal stiffness;Osteopenia;Pain;Posture abnormal;Skeletal injury;Tooth loss;Wrist fracture,,,,,204919852,1,2008,2008,,,204919852,1,HIV infection
20496448,204964483,3,F,20190101,20220919,20220221,20220923,EXP,,US-GILEAD-2022-0569151,GILEAD,,,,A,M,Y,74.83,KG,20220923,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Diabetes mellitus;Emotional distress;Mobility decreased;Pain;Renal impairment,204964483,OT,,,204964483,1,2015,201907,,,204964483,1,HIV infection
20527677,205276772,2,F,,20220620,20220228,20220708,EXP,,FR-GLAXOSMITHKLINE-FR2022035414,GLAXOSMITHKLINE,,,,,,Y,,,20220708,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Myocardial infarction,205276772,OT,,,,,,,,,205276772,1,HIV infection
20527678,205276782,2,F,,20220620,20220228,20220708,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2022035414,VIIV,,,,,,Y,,,20220708,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Myocardial infarction,205276782,OT,,,,,,,,,205276782,1,HIV infection
20569252,205692522,2,F,20090101,20220818,20220308,20220823,EXP,,US-GILEAD-2022-0572407,GILEAD,,,,A,F,Y,,,20220823,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Mobility decreased;Multiple fractures;Osteoporosis;Pain,205692522,OT,,,205692522,1,2007,2018,,,205692522,1,HIV infection
20570688,205706882,2,F,20150701,20220921,20220309,20220927,EXP,,US-GILEAD-2022-0572922,GILEAD,,40,YR,A,M,Y,92.971,KG,20220926,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Blood creatinine increased;Depression;Dysstasia;Emotional distress;Osteopenia;Osteoporosis;Pain;Renal impairment,205706882,OT,,,205706882,1,2002,201612,,,205706882,1,HIV infection
20574834,205748343,3,F,,20220729,20220310,20220810,EXP,,FR-AUROBINDO-AUR-APL-2022-007338,AUROBINDO,"Landman R, de Truchis P, Assoumou L, Lambert S, Bellet J, Amat K, et al... A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.. The Lancet HIV.. 2022;9 (2):e79-90",,,A,,Y,,,20220810,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Drug resistance;Gene mutation;Myocardial infarction;Pathogen resistance;Virologic failure,205748343,OT,,,,,,,,,205748343,1,HIV infection
20592844,205928443,3,F,20200115,20220707,20220315,20220720,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-037237,BRISTOL MYERS SQUIBB,,18,YR,A,F,Y,,,20220720,,HP,ZW,ZW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,205928443,OT,,,205928443,1,20190122,20191217,330,DAY,205928443,1,HIV infection
20602708,206027084,4,F,20200115,20220708,20220316,20220711,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2022GSK047270,VIIV,,,,,,Y,,,20220711,,HP,ZW,ZW,SUSTIVA,Abortion spontaneous;Exposure during pregnancy,206027084,OT,,,206027084,1,20190122,20191217,329,DAY,206027084,1,HIV infection
20602710,206027103,3,F,20200115,20220708,20220316,20220711,EXP,,ZW-GLAXOSMITHKLINE-ZW2022GSK047270,GLAXOSMITHKLINE,,,,,,Y,,,20220711,,HP,ZW,ZW,SUSTIVA,Abortion spontaneous;Exposure during pregnancy,206027103,OT,,,206027103,1,20190122,20191217,329,DAY,206027103,1,HIV infection
20612453,206124532,2,F,,20220608,20220318,20220822,EXP,,CA-MYLANLABS-2022M1020580,MYLAN,,54,YR,,M,Y,,,20220822,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,206124532,OT,,,,,,,,,206124532,1,Bipolar disorder
20649018,206490183,3,F,20130101,20220630,20220329,20220703,EXP,,US-GILEAD-2022-0575268,GILEAD,,,,A,M,Y,63.492,KG,20220703,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Bone pain;Emotional distress;Exercise tolerance decreased;Foot fracture;Multiple fractures;Osteoporosis;Pain,206490183,OT,,,206490183,1,2005,2013,,,206490183,1,HIV infection
20669823,206698233,3,F,,20220718,20220404,20220721,EXP,,FR-MYLANLABS-2022M1024088,MYLAN,"Yazdanpanah Y, Leibowitch J, Bellet J, Lefebvre B, Allavena C, Katlama C, et al.. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.. Lancet HIV. 2022;9:e79-e90",,,A,,Y,,,20220721,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Drug resistance;Gene mutation;Myocardial infarction;Pathogen resistance;Virologic failure,206698233,OT,,,,,,,,,206698233,1,HIV infection
20694110,206941104,4,F,,20220912,20220411,20220914,EXP,,CA-ROCHE-3065639,ROCHE,,44,YR,,M,Y,,,20220915,,HP,CA,,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,206941104,HO,,,,,,,,,206941104,1,Depression
20716424,207164243,3,F,,20220713,20220416,20220725,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2022-017777,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20220725,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,207164243,OT,,,,,,,,,207164243,1,Product used for unknown indication
20729014,207290142,2,F,20120901,20220822,20220420,20220825,PER,,US-GILEAD-2022-0578486,GILEAD,,55,YR,A,M,Y,97.522,KG,20220825,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Back pain;Dysstasia;Emotional distress;Fatigue;Gait disturbance;General physical health deterioration;Pain;Pollakiuria;Renal failure;Renal pain,207290142,OT,,,207290142,1,2006,2013,,,207290142,1,HIV infection
20731145,207311452,2,F,,20220826,20220420,20220906,EXP,,CA-MYLANLABS-2022M1028568,MYLAN,,54,YR,,M,Y,,,20220906,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,207311452,OT,,,,,,,,,207311452,1,Bipolar disorder
20757098,207570982,2,F,,20220420,20220427,20220712,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK069737,GLAXOSMITHKLINE,,,,,,Y,,,20220712,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,207570982,OT,,,,,,,,,207570982,1,Bipolar disorder
20757163,207571632,2,F,,20220420,20220427,20220712,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK069612,GLAXOSMITHKLINE,,,,,,Y,,,20220712,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,207571632,OT,,,,,,,,,207571632,1,Bipolar disorder
20859131,208591312,2,F,20120101,20220818,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,SUSTIVA,Abdominal pain lower;Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Depression;Emotional distress;Muscular weakness;Osteonecrosis;Osteoporosis;Pain;Pain in extremity;Periarthritis;Quality of life decreased,208591312,OT,,,208591312,1,2005,201703,,,208591312,1,HIV infection
20859502,208595022,2,F,20101001,20220630,20220523,20220704,EXP,,US-GILEAD-2022-0582516,GILEAD,,46,YR,A,M,Y,111.11,KG,20220704,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Dysstasia;Emotional distress;Gait disturbance;Pain;Renal failure,208595022,OT,,,208595022,1,2006,201904,,,208595022,1,HIV infection
20859579,208595793,3,F,,20220927,20220523,20220930,EXP,,CA-GILEAD-2022-0582268,GILEAD,,54,YR,A,M,Y,,,20220930,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208595793,HO,,,,,,,,,208595793,1,Product used for unknown indication
20861199,208611992,2,F,,20220719,20220523,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-039077,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20220728,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208611992,HO,,,,,,,,,208611992,1,HIV infection
20862425,208624252,2,F,,20220810,20220523,20220825,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-039291,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20220825,,CN,CA,CA,EFAVIRENZ;SUSTIVA,Adverse event;Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities,208624252,HO,,,,,,,,,208624252,1,HIV infection
20864134,208641342,2,F,20140101,20220714,20220523,20220718,EXP,,US-GILEAD-2022-0582465,GILEAD,,,,A,M,Y,134.69,KG,20220718,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone demineralisation;Emotional distress;General physical health deterioration;Osteopenia;Osteoporosis;Pain,208641342,OT,,,208641342,1,2006,201410,,,208641342,1,HIV infection
20866089,208660892,2,F,20140801,20220908,20220524,20220913,EXP,,US-GILEAD-2022-0582630,GILEAD,,51,YR,A,F,Y,79.365,KG,20220913,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Back pain;Chronic kidney disease;Dysstasia;Emotional distress;Exercise tolerance decreased;Fatigue;Gait disturbance;Hyperparathyroidism;Insomnia;Osteopenia;Osteoporosis;Pain;Pollakiuria;Quality of life decreased;Renal impairment;Renal pain,208660892,OT,,,208660892,1,2009,2009,40,MON,208660892,1,HIV infection
20871993,208719932,2,F,,20210504,20220525,20220708,EXP,,SE-VIIV HEALTHCARE LIMITED-SE2021267531,VIIV,,,,,,Y,,,20220708,,HP,SE,SE,EFAVIRENZ,Drug resistance,208719932,OT,,,,,,,,,208719932,1,HIV infection
20871996,208719962,2,F,,20210504,20220525,20220708,EXP,,SE-GLAXOSMITHKLINE-SE2021267531,GLAXOSMITHKLINE,,,,,,Y,,,20220708,,HP,SE,SE,EFAVIRENZ,Drug resistance,208719962,OT,,,,,,,,,208719962,1,HIV infection
20879536,208795362,2,F,,20220914,20220526,20220919,EXP,,CA-009507513-2205CAN005187,MERCK,,52,YR,,M,Y,,,20220919,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,208795362,OT,,,,,,,,,208795362,1,HIV infection
20884066,208840662,2,F,,20220926,20220527,20220929,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK084848,VIIV,,,,,,Y,,,20220929,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,208840662,OT,,,,,,,,,208840662,1,HIV infection
20884074,208840742,2,F,,20220926,20220527,20220929,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK084848,GLAXOSMITHKLINE,,,,,,Y,,,20220929,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,208840742,DE,,,,,,,,,208840742,1,HIV infection
20891456,208914566,6,F,,20220715,20220530,20220722,EXP,,ES-JNJFOC-20220557464,JOHNSON AND JOHNSON,,41,YR,A,M,Y,,,20220722,,HP,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,208914566,OT,,,208914566,4,200501,201501,,,208914566,1,HIV infection
20895023,208950237,7,F,20100629,20220721,20220531,20220725,EXP,,GB-GLAXOSMITHKLINE-GB2022083878,GLAXOSMITHKLINE,,,,,,Y,,,20220725,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Trisomy 18;Ultrasound antenatal screen,208950237,CA,,,208950237,1,20090101,20100610,525,DAY,208950237,1,Antiretroviral therapy
20895036,208950367,7,F,20100629,20220721,20220531,20220725,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2022083878,VIIV,,,,,,Y,,,20220725,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Trisomy 18;Ultrasound antenatal screen,208950367,DE,,,208950367,1,20090101,20100610,525,DAY,208950367,1,Antiretroviral therapy
20898424,2089842433,33,F,20120521,20220909,20220601,20220924,EXP,,GB-ABBVIE-22K-167-4414502-00,ABBVIE,,43,YR,,F,Y,,,20220924,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,2089842433,CA,,,2089842433,1,20100610,20180205,19,DAY,2089842433,1,HIV infection
20898441,208984412,2,F,,20220912,20220601,20220920,EXP,,CA-AUROBINDO-AUR-APL-2022-018761,AUROBINDO,,54,YR,,M,Y,,,20220920,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208984412,HO,,,,,,,,,208984412,1,Psychotic disorder
20907064,209070643,3,F,,20220628,20220602,20220705,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172602",BOEHRINGER INGELHEIM,,41,YR,A,M,Y,,,20220705,,HP,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,209070643,OT,,,209070643,1,1995,200501,73,MON,209070643,1,HIV infection
20907220,209072202,2,F,,20220808,20220602,20220817,EXP,,CA-ALLERGAN-2217864US,ALLERGAN,,,,,M,Y,,,20220817,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209072202,HO,,,,,,,,,209072202,1,Psychotic disorder
20910420,209104206,6,F,,20220629,20220603,20220711,EXP,,ES-009507513-2205ESP007868,MERCK,"Puertas MC, Ploumidis G,Ploumidis M, Fumero E, Clotet B, Walworth CM et al.. Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report.. The Lancet Microbe. 2020;1(3):e130-5",41,YR,,M,Y,,,20220711,,HP,ES,ES,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Therapy non-responder;Virologic failure,209104206,OT,,,209104206,1,200812,201501,,,209104206,1,HIV infection
20911260,209112602,2,F,20220101,20220715,20220603,20220722,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2022EME086667,VIIV,,,,,,Y,,,20220722,,MD,RU,RU,EFAVIRENZ,Rash;Toxic skin eruption,209112602,OT,,,209112602,1,20220323,20220407,15,DAY,209112602,1,HIV infection
20918819,209188193,3,F,,20220809,20220606,20220815,EXP,,CA-ROCHE-3108784,ROCHE,,54,YR,,M,Y,,,20220815,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,209188193,DE,,,,,,,,,209188193,1,Bipolar disorder
20922913,209229134,4,F,,20220713,20220607,20220727,EXP,,ES-AUROBINDO-AUR-APL-2022-020446,AUROBINDO,"Puertas MC, Ploumidis G,Ploumidis M, Fumero E, Clotet B, Walworth CM et al... Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report.. The Lancet Microbe. 2020;1(3):e130-e135",41,YR,,M,Y,,,20220727,,MD,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,209229134,OT,,,209229134,1,200501,200501,,,209229134,1,HIV infection
20923847,209238473,3,F,,20220913,20220607,20220920,EXP,,CA-ROCHE-3109019,ROCHE,,54,YR,,M,Y,,,20220920,,HP,CA,,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209238473,HO,,,,,,,,,209238473,1,Depression
20965915,209659152,2,F,,20220620,20220616,20220702,EXP,,DK-AUROBINDO-AUR-APL-2022-019522,AUROBINDO,"Gulden T, Yahyavi SK, Lodding IP, Jensen JB, Blomberg Jensen M.. Severe hypocalcemia due to hypoparathyroidism associated with HIV: A case report. Bone Reports. 2021;15:101119",67,YR,,M,Y,,,20220702,,HP,DK,DK,EFAVIRENZ,Dehydration;Diarrhoea;Hypocalcaemia;Myalgia;Nausea;Off label use;Vomiting,209659152,HO,,,,,,,,,209659152,1,HIV infection
20966859,2096685913,13,F,20100629,20220920,20220616,20220926,EXP,GB-AUROBINDO-AUR-APL-2018-033634,GB-STRIDES ARCOLAB LIMITED-2018SP005378,STRIDES,,43,YR,,F,Y,43,KG,20220926,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Drug abuse;Hepatic cytolysis;Hydrops foetalis;Intentional product misuse;Maternal exposure during pregnancy,2096685913,CA,,,2096685913,1,20100610,20180205,4,MON,2096685913,1,HIV infection
20968050,209680504,4,F,,20220919,20220616,20220924,EXP,,PHHY2017GB177929,NOVARTIS,,85,YR,,M,Y,,,20220924,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,209680504,OT,,,209680504,8,,,152,DAY,209680504,1,Cardiovascular event prophylaxis
20994170,209941705,5,F,,20220718,20220622,20220721,EXP,,ES-MYLANLABS-2022M1045944,MYLAN,"Puertas MC, Ploumidis G,Ploumidis M, Fumero E, Clotet B, Walworth CM et al.. Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report.. The Lancet Microbe.. 2020;1(3):e130-e135",41,YR,,M,Y,,,20220721,,HP,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,209941705,OT,,,209941705,2,200501,200501,,,209941705,1,HIV infection
21022167,210221674,4,F,,20220808,20220629,20220810,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2022098218,VIIV,,,,,,Y,,,20220810,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,210221674,CA,,,210221674,1,20090101,20100610,526,DAY,210221674,1,Product used for unknown indication
21022189,210221894,4,F,,20220808,20220629,20220810,EXP,,GB-GLAXOSMITHKLINE-GB2022098218,GLAXOSMITHKLINE,,,,,,Y,,,20220810,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,210221894,CA,,,210221894,1,20090101,20100610,526,DAY,210221894,1,Product used for unknown indication
21032324,210323241,1,I,20090618,20220623,20220701,20220701,EXP,,FR-ROCHE-2233267,ROCHE,"Reporter known company, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).. Chemical biology + drug design.. 2018;:-.",47,YR,,M,Y,,,20220701,,HP,FR,FR,EFAVIRENZ,Drug resistance;Viral mutation identified,210323241,OT,,,,,,,,,210323241,1,HIV infection
21033784,210337841,1,I,,20220623,20220701,20220701,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2022AMR098173,VIIV,,,,,,Y,,,20220701,,MD,BR,BR,EFAVIRENZ,Drug hypersensitivity;Pathogen resistance;Product use issue;Rash;Treatment failure;Treatment noncompliance;Viral mutation identified,210337841,OT,,,,,,,,,210337841,1,Product used for unknown indication
21033786,210337861,1,I,20010101,20220624,20220701,20220701,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022EME097938,VIIV,,,,,,Y,,,20220701,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Dyslipidaemia;Endocarditis;Hypertension,210337861,OT,,,210337861,1,2018,202107,,,210337861,1,HIV infection
21033830,210338301,1,I,20010101,20220624,20220701,20220701,EXP,,PT-GLAXOSMITHKLINE-PT2022EME097938,GLAXOSMITHKLINE,,,,,,Y,,,20220701,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Dyslipidaemia;Endocarditis;Hypertension,210338301,HO,,,210338301,1,2018,202107,,,210338301,1,HIV infection
21036366,210363662,2,F,20120101,20220617,20220702,20220702,EXP,,GB-MACLEODS PHARMA UK LTD-MAC2022036261,MACLEODS,,,,,,Y,,,20220702,,CN,GB,GB,EFAVIRENZ,Arthritis;Knee operation,210363662,OT,,,,,,,,,210363662,1,HIV infection
21038870,210388701,1,I,20210101,20220620,20220704,20220704,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-2022-061745,BRISTOL MYERS SQUIBB,,43,YR,A,M,Y,,,20220704,,MD,AT,AT,EFAVIRENZ,Drug resistance;Neoplasm malignant,210388701,OT,,,210388701,3,2017,2017,2,MON,210388701,1,Product used for unknown indication
21039020,210390201,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04099,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research And Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390201,OT,,,,,,,,,210390201,1,HIV infection
21039024,210390241,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04094,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2022;38 (6):455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390241,OT,,,,,,,,,210390241,1,HIV infection
21039027,210390271,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04085,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research and Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390271,OT,,,,,,,,,210390271,1,HIV infection
21039030,210390301,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04087,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids research and human retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390301,OT,,,,,,,,,210390301,1,HIV infection
21039033,210390331,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04090,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research And Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390331,OT,,,,,,,,,210390331,1,HIV infection
21039034,210390341,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04092,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2022;38 (6):455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390341,OT,,,,,,,,,210390341,1,HIV infection
21039035,210390351,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04100,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research and Human Retroviruses. 2022;38:6:455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390351,OT,,,,,,,,,210390351,1,HIV infection
21039038,210390381,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04093,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2022;38:6:455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390381,OT,,,,,,,,,210390381,1,HIV infection
21039039,210390391,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04096,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug resistance, rather than low Tenofovir levels in blood or urine, is associated with Tenofovir, Emtricitabine, and Efavirenz failure in resource-limited settings. Aids research and human retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390391,OT,,,,,,,,,210390391,1,HIV infection
21039040,210390401,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04097,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2022;38 (6):455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390401,OT,,,,,,,,,210390401,1,HIV infection
21039041,210390411,1,I,,20220620,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04091,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research and Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390411,OT,,,,,,,,,210390411,1,HIV infection
21041731,210417311,1,I,,20220620,20220705,20220705,EXP,,ZA-CIPLA LTD.-2022ZA04095,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research And Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220701,,MD,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210417311,OT,,,,,,,,,210417311,1,HIV infection
21041732,210417321,1,I,,20220620,20220705,20220705,EXP,,ZA-CIPLA LTD.-2022ZA04098,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research and Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220701,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210417321,OT,,,,,,,,,210417321,1,HIV infection
21041733,210417331,1,I,,20220620,20220705,20220705,EXP,,ZA-CIPLA LTD.-2022ZA04089,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research And Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220701,,MD,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210417331,OT,,,,,,,,,210417331,1,HIV infection
21041734,210417341,1,I,,20220620,20220705,20220705,EXP,,ZA-CIPLA LTD.-2022ZA04088,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS Research and Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220701,,MD,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210417341,OT,,,,,,,,,210417341,1,HIV infection
21042191,210421911,1,I,,20220622,20220705,20220705,EXP,,NA-CIPLA LTD.-2022NA04150,CIPLA,"Kakubu AMM, Katoto PDMC, Bikinesi T, Liswaniso ES.. A case of undisclosed prior exposure to antiretroviral therapy (ART) and early virologic failure that improved on a pre-emptive third-line ART regimen. GERMS. 2022;12 (1):102 to 106",53,YR,,M,Y,,,20220705,,MD,,,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210421911,OT,,,,,,,,,210421911,1,HIV infection WHO clinical stage I
21045327,210453271,1,I,,20220628,20220706,20220706,EXP,,IN-STRIDES ARCOLAB LIMITED-2022SP008232,STRIDES,"Mangal V, Murari T, Gaikwad S, Kaur K.. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy - A case report.. Indian-J-Nephrol. 2022;32(2):175-178",54,YR,,F,Y,,,20220706,,HP,IN,IN,EFAVIRENZ;EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Nephrolithiasis,210453271,HO,,,210453271,2,,,6,YR,210453271,1,HIV infection
21047238,210472381,1,I,,20220627,20220706,20220706,EXP,,FR-MYLANLABS-2022M1050473,MYLAN,"Joharjy H, Pisella PJ, Audo I, Le-Lez ML. A Rare Case of Didanosine-Induced Mid-Peripheral Chorioretinal Atrophy Identified Incidentally 11 Years after the Drug Cessation. Medicina-Kaunas 2022;58(6):1-8.",42,YR,,F,Y,51,KG,20220706,,HP,FR,FR,EFAVIRENZ,Retinopathy,210472381,OT,,,210472381,1,2004,2011,,,210472381,1,HIV infection
21047694,210476941,1,I,,20220701,20220706,20220706,EXP,,DE-GLAXOSMITHKLINE-DE2021EME035635,GLAXOSMITHKLINE,,,,,,Y,,,20220706,,MD,DE,DE,EFAVIRENZ,Drug resistance,210476941,OT,,,,,,,,,210476941,1,HIV infection
21047773,210477731,1,I,,20220701,20220706,20220706,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2021EME035635,VIIV,,,,,,Y,,,20220706,,MD,DE,DE,EFAVIRENZ,Drug resistance,210477731,OT,,,,,,,,,210477731,1,HIV infection
21047841,210478411,1,I,,20220628,20220706,20220706,EXP,,IN-MYLANLABS-2022M1050534,MYLAN,"Mangal V, Murari T, Gaikwad S, Kaur K. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy - A case report. Indian-J-Nephrol 2022;32(2):175-178.",54,YR,,F,Y,,,20220706,,HP,IN,IN,EFAVIRENZ;EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Fanconi syndrome acquired;Femoral neck fracture;Hydronephrosis;Nephrolithiasis;Osteomalacia,210478411,HO,,,210478411,1,,,6,YR,210478411,1,HIV infection
21054689,210546891,1,I,20050801,20220704,20220707,20220707,EXP,,PT-MYLANLABS-2022M1050688,MYLAN,,54,YR,,M,Y,,,20220707,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,210546891,OT,,,210546891,3,200209,200504,,,210546891,1,HIV infection
21061351,210613511,1,I,,20220630,20220709,20220709,EXP,,CA-TEVA-2022-CA-2052424,TEVA,,54,YR,A,M,Y,,,20220709,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,210613511,DE,,,,,,,,,210613511,1,HIV infection
21062995,210629951,1,I,,20220707,20220711,20220711,EXP,,US-GILEAD-2022-0588833,GILEAD,,,,A,M,Y,,,20220711,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Bone disorder,210629951,DS,,,,,,,,,210629951,1,HIV infection
21068949,210689491,1,I,,20220705,20220712,20220712,EXP,,CA-MYLANLABS-2022M1052091,MYLAN,,,,,M,Y,,,20220712,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,210689491,DE,,,,,,,,,210689491,1,Product used for unknown indication
21071279,210712791,1,I,,20220708,20220712,20220712,EXP,,CA-ABBVIE-22K-028-4465122-00,ABBVIE,,,,,M,Y,,,20220712,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,210712791,OT,,,,,,,,,210712791,1,Product used for unknown indication
21071580,210715801,1,I,,20220629,20220712,20220712,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2022-066770,BRISTOL MYERS SQUIBB,"Joharjy H, Pisella P, Audo I, Le-Lez M. A rare case of didanosine-induced mid-peripheral chorioretinal atrophy identified incidentally 11 Years after the drug cessation. Medicina. 2022; 1-8. 10.3390/medicina58060735",42,YR,A,F,Y,51,KG,20220712,,HP,FR,FR,EFAVIRENZ,Retinal degeneration,210715801,OT,,,210715801,3,201112,202110,118,MON,210715801,1,HIV infection
21073285,210732851,1,I,20050801,20220704,20220712,20220712,EXP,,PT-JNJFOC-20220708498,JOHNSON AND JOHNSON,,54,YR,A,M,Y,,,20220713,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,210732851,OT,,,210732851,2,200209,200504,,,210732851,1,HIV infection
21073704,210737041,1,I,,20220705,20220713,20220713,EXP,,FR-CELLTRION INC.-2022FR010788,CELLTRION,"Laparra A, Lerolle N, Gerin M, Cheret A, Castro N, Gallien S, et al.. Tumor necrosis factor-alpha inhibitors for extended or severe neurological immune reconstitution inflammatory syndrome in HIV-infected patients. AIDS. 2021;35(6):995-1001",,,,,Y,,,20220713,,HP,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Off label use,210737041,OT,,,210737041,2,,,16,DAY,210737041,1,Immune reconstitution inflammatory syndrome associated tuberculosis
21078450,210784503,3,F,20220601,20220808,20220713,20220810,EXP,,US-GILEAD-2022-0588983,GILEAD,,58,YR,A,M,Y,94.785,KG,20220810,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Blood triglycerides increased;Diabetic retinopathy;Hyperglycaemia;Hypoglycaemia;Type 2 diabetes mellitus,210784503,OT,,,210784503,1,20220301,20220301,128,DAY,210784503,1,Product used for unknown indication
21078983,210789831,1,I,,20220711,20220713,20220713,EXP,,ZA-GILEAD-2022-0589123,GILEAD,,,,I,M,Y,2.2,KG,20220713,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby;Sepsis neonatal,210789831,OT,,,,,,,,,210789831,1,Product used for unknown indication
21079053,210790531,1,I,,20220711,20220713,20220713,EXP,,US-GILEAD-2022-0589316,GILEAD,,,,A,M,Y,,,20220713,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,210790531,OT,,,,,,,,,210790531,1,Product used for unknown indication
21080303,210803032,2,F,20050801,20220722,20220714,20220805,EXP,,PT-AUROBINDO-AUR-APL-2022-025665,AUROBINDO,,54,YR,,M,Y,,,20220805,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,210803032,OT,,,210803032,2,200209,,,,210803032,1,HIV infection
21081693,210816931,1,I,20010101,20220711,20220714,20220714,EXP,,PT-MYLANLABS-2022M1077749,MYLAN,,46,YR,,M,Y,,,20220714,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Dyslipidaemia;Endocarditis;Hypertension,210816931,HO,,,210816931,1,2012,2018,,,210816931,1,HIV infection
21081813,210818131,1,I,20220101,20220707,20220714,20220714,EXP,,CO-VIIV HEALTHCARE LIMITED-CO2022AMR104745,VIIV,,,,,,Y,,,20220714,,MD,CO,CO,EFAVIRENZ,Hypertension;Myocardial infarction,210818131,OT,,,210818131,1,20220502,2022,,,210818131,1,HIV infection
21086868,210868681,1,I,,20220708,20220715,20220715,EXP,,DE-ABBVIE-21K-062-3784915-00,ABBVIE,,57,YR,,M,Y,,,20220715,,CN,DE,DE,EFAVIRENZ,Drug resistance,210868681,OT,,,,,,,,,210868681,1,HIV infection
21086894,210868941,1,I,,20220630,20220715,20220715,EXP,,DE-MACLEODS PHARMACEUTICALS US LTD-MAC2022036410,MACLEODS,,,,,,Y,,,20220714,,MD,DE,DE,EFAVIRENZ,Drug resistance,210868941,OT,,,,,,,,,210868941,1,HIV infection
21087570,210875701,1,I,,20220705,20220715,20220715,EXP,,CA-MYLANLABS-2022M1078143,MYLAN,,,,,M,Y,,,20220715,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,210875701,OT,,,,,,,,,210875701,1,Product used for unknown indication
21092489,210924891,1,I,20010101,20220706,20220718,20220718,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-069835,BRISTOL MYERS SQUIBB,,46,YR,A,M,Y,,,20220718,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Dyslipidaemia;Endocarditis;Hypertension,210924891,HO,,,210924891,1,2012,2018,6,YR,210924891,1,HIV infection
21097237,210972371,1,I,,20220704,20220719,20220719,EXP,,ZA-CIPLA LTD.-2022ZA04311,CIPLA,"Thomson KF, Mahlobo F, Reddy DL. Splenic hydatid disease in pregnancy. Southern African Journal of HIV Medicine. 2022;23 (1):1 to 4",41,YR,,F,Y,,,20220714,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy;Premature delivery,210972371,OT,,,210972371,2,,,5,DAY,210972371,1,HIV infection
21103552,211035521,1,I,20010101,20220707,20220720,20220720,EXP,,PT-AUROBINDO-AUR-APL-2022-026217,AUROBINDO,,46,YR,,M,Y,,,20220720,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Dyslipidaemia;Endocarditis;Hypertension,211035521,HO,,,211035521,1,2001,2018,,,211035521,1,Hepatitis C
21112325,211123251,1,I,20220720,,20220721,20220721,DIR,623970,,FDA-CTU,,50,YR,,M,N,,,20220721,N,PH,US,,EFAVIRENZ,Hospitalisation,211123251,HO,211123251,HP,211123251,1,20181113,,,,211123251,1,HIV infection
21121453,211214531,1,I,,20220715,20220722,20220722,EXP,,ES-GSK-ES2022GSK108143,GLAXOSMITHKLINE,,,,,,Y,,,20220722,,HP,ES,ES,EFAVIRENZ,Adrenal insufficiency;Asthenia;Contusion;Cushing's syndrome;Cushingoid;Drug interaction;Exercise tolerance decreased;Fat tissue increased;Ill-defined disorder;Virologic failure,211214531,OT,,,,,,,,,211214531,1,Asthma
21130492,211304921,1,I,,20220712,20220726,20220726,EXP,,IN-BIOLOGICAL E. LTD-2131241,BIOLOGICAL E.,"Mangal V, Murari T, Gaikwad SN, Kaur K. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy-A case report. Indian Journal of Nephrology. 2022 Mar 11, 32(2):175-178. DOI: 10.4103/ijn.IJN_456_20",54,YR,,F,Y,,,20220726,,HP,IN,IN,EFAVIRENZ,Condition aggravated;Drug ineffective,211304921,HO,,,,,,,,,211304921,1,Pulmonary embolism
21138033,211380331,1,I,,20220720,20220727,20220727,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022AMR109217,VIIV,,,,,,Y,,,20220727,,CN,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,211380331,OT,,,211380331,1,2020,,,,211380331,1,HIV infection
21138061,211380611,1,I,,20220720,20220727,20220727,EXP,,CA-GSK-CA2022AMR109217,GLAXOSMITHKLINE,,,,,,Y,,,20220727,,CN,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,211380611,OT,,,211380611,1,2020,,,,211380611,1,HIV infection
21141067,211410671,1,I,20060701,20220725,20220728,20220728,EXP,,PT-GILEAD-2022-0591091,GILEAD,,54,YR,A,M,Y,,,20220728,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211410671,OT,,,211410671,1,200607,200504,,,211410671,1,HIV infection
21142753,211427531,1,I,,20220509,20220728,20220728,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-2022-041051,BRISTOL MYERS SQUIBB,"Mangal V, Murari T, Someshwar , Gaikwad N, Kaur K. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy - a case report. Indian Journal of Nephrology. 2022 Mar 11; 32(2): 175-8. 10.4103/ijn.IJN_456_20",54,YR,A,F,Y,,,20220728,,MD,IN,IN,EFAVIRENZ,Hydronephrosis;Nephrolithiasis,211427531,OT,,,,,,,,,211427531,1,Antiretroviral therapy
21143772,211437722,2,F,,20220725,20220728,20220801,EXP,,NVSC2022CH167856,NOVARTIS,"Greiner M, Treichler G, Morel C, Camenzind D, Neumayr A, Blum J et al. Parasitaere Infektionen: Panzytopenie und akutes Nierenversagen / Parasitic infections: Pancytopenia and acute renal failure. SCHWEIZERISCHES MEDIZIN-FORUM. 2022;22 (29-30):487-90",62,YR,,M,Y,54,KG,20220801,,HP,CH,CH,EFAVIRENZ,Acute kidney injury,211437722,HO,,,,,,,,,211437722,1,Oedema peripheral
21145130,211451301,1,I,,20220719,20220729,20220729,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-081043,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20220729,,CN,CA,CA,SUSTIVA,Death,211451301,DE,,,,,,,,,211451301,1,HIV infection
21148760,211487601,1,I,,20220726,20220729,20220729,EXP,,CA-AstraZeneca-2022A267587,ASTRAZENECA,,54,YR,,M,Y,,,20220729,,MD,CA,,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,211487601,DE,,,,,,,,,211487601,1,Bipolar disorder
21158239,211582391,1,I,20060701,20220725,20220801,20220801,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022112005,VIIV,,,,,,Y,,,20220801,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211582391,OT,,,211582391,1,200209,200504,,,211582391,1,HIV infection
21158241,211582411,1,I,20060701,20220725,20220801,20220801,EXP,,PT-GSK-PT2022112005,GLAXOSMITHKLINE,,,,,,Y,,,20220801,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211582411,OT,,,211582411,1,200209,200504,,,211582411,1,HIV infection
21161923,211619231,1,I,,20220719,20220802,20220802,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-083119,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20220802,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Death,211619231,DE,,,,,,,,,211619231,1,HIV infection
21163555,211635551,1,I,,20220726,20220802,20220802,EXP,,CA-AstraZeneca-2022A269156,ASTRAZENECA,,,,,M,Y,,,20220803,,MD,CA,,SUSTIVA,Depression;Drug interaction,211635551,HO,,,,,,,,,211635551,1,Product used for unknown indication
21163633,211636336,6,F,20171006,20220915,20220802,20220926,EXP,,GB-ABBVIE-22P-167-4487400-00,ABBVIE,,16,WK,,M,Y,,,20220926,,HP,GB,GB,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,211636336,DE,,,211636336,11,20171006,20180205,122,DAY,211636336,1,Maternal exposure timing unspecified
21166263,211662631,1,I,,20220726,20220803,20220803,EXP,,CA-AstraZeneca-2022A267561,ASTRAZENECA,,54,YR,,M,Y,,,20220803,,MD,CA,,SUSTIVA,Depression;Drug interaction,211662631,OT,,,,,,,,,211662631,1,Product used for unknown indication
21167014,211670141,1,I,,20220726,20220803,20220803,EXP,,CA-AstraZeneca-2022A270092,ASTRAZENECA,,54,YR,,M,Y,,,20220803,,MD,CA,,SUSTIVA,Depression;Drug interaction,211670141,OT,,,,,,,,,211670141,1,Product used for unknown indication
21167110,211671101,1,I,20200801,20220727,20220803,20220803,EXP,,DK-GSK-DK2022GSK113937,GLAXOSMITHKLINE,"Mens H, Fjordside L, Fonager J, Gerstoft J. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infectious Disease Reports. 2022;14(4):501-504",,,,,Y,,,20220803,,HP,DK,DK,EFAVIRENZ,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,211671101,OT,,,,,,,,,211671101,1,HIV infection
21167111,211671111,1,I,20200801,20220727,20220803,20220803,EXP,,DK-VIIV HEALTHCARE LIMITED-DK2022GSK113937,VIIV,"Mens H, Fjordside L, Fonager J, Gerstoft J. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infectious Disease Reports. 2022;14(4):501-504",,,,,Y,,,20220803,,HP,DK,DK,EFAVIRENZ,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,211671111,OT,,,,,,,,,211671111,1,HIV infection
21170673,211706731,1,I,,20220725,20220804,20220804,EXP,,CH-MYLANLABS-2022M1082160,MYLAN,"Greiner M, Treichler G, Morela C, Camenzincia D, Neumayr A. Blum J et al.. Panzytopenie und akutes Nierenversagen. Swiss Medical forum. 2022;1-6",62,YR,,M,Y,54,KG,20220804,,MD,CH,CH,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Kidney fibrosis;Renal failure,211706731,OT,,,,,,,,,211706731,1,HIV infection
21172774,211727741,1,I,,20220726,20220804,20220804,EXP,,CA-AstraZeneca-2022A267471,ASTRAZENECA,,54,YR,,M,Y,,,20220804,,MD,CA,,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,211727741,OT,,,,,,,,,211727741,1,Bipolar disorder
21177192,211771921,1,I,20050801,20220728,20220805,20220805,EXP,,PT-TEVA-2022-PT-2061184,TEVA,,54,YR,A,M,Y,,,20220805,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211771921,OT,,,211771921,2,200607,200504,2,YR,211771921,1,HIV infection
21193496,211934962,2,F,,20220816,20220810,20220829,EXP,,UG-AUROBINDO-AUR-APL-2022-031724,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children.. Acta Paediatrica... 2020;109:2706-16",10,YR,,,Y,,,20220829,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,211934962,OT,,,,,,,,,211934962,1,HIV infection
21193504,211935041,1,I,,20220803,20220810,20220810,EXP,,UG-AUROBINDO-AUR-APL-2022-031762,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al.. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica. 2020;109:2706-16",3,YR,,,Y,,,20220810,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,211935041,OT,,,,,,,,,211935041,1,HIV infection
21193670,211936701,1,I,,20220805,20220810,20220810,EXP,,CA-009507513-2208CAN003680,MERCK,,,,,M,Y,,,20220810,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,211936701,OT,,,,,,,,,211936701,1,Product used for unknown indication
21194880,211948801,1,I,,20220802,20220810,20220810,EXP,,CA-AstraZeneca-2022A277353,ASTRAZENECA,,54,YR,,M,Y,,,20220810,,MD,CA,,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,211948801,HO,,,,,,,,,211948801,1,Depression
21198591,211985911,1,I,,20220805,20220811,20220811,EXP,,CA-009507513-2208CAN003665,MERCK,,54,YR,,M,Y,,,20220811,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,211985911,OT,,,,,,,,,211985911,1,Product used for unknown indication
21199407,211994071,1,I,,20220803,20220811,20220811,EXP,,UG-AUROBINDO-AUR-APL-2022-031750,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica. 2020;109:2706-16",9,YR,,,Y,,,20220811,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,211994071,OT,,,,,,,,,211994071,1,HIV infection
21199788,211997881,1,I,,20220808,20220811,20220811,EXP,,CA-ROCHE-3156506,ROCHE,,,,,M,Y,,,20220811,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,211997881,HO,,,,,,,,,211997881,1,Product used for unknown indication
21204388,212043882,2,F,,20220801,20220812,20220812,EXP,,CA-SPECGX-T202201712,SPECGX,"Abramson DW, Quinn DK, Stern TA. Methadone?associated QTc prolongation: A case report and review of the literature. J Clin Psychiatry. 2008;10(6):470-6",47,YR,,F,Y,,,20220812,,MD,US,US,EFAVIRENZ,Drug interaction;Electrocardiogram QT prolonged;Pneumothorax spontaneous;Torsade de pointes;Ventricular tachycardia,212043882,OT,,,,,,,,,212043882,1,Product used for unknown indication
21211309,212113091,1,I,,20220809,20220815,20220815,EXP,,CA-ROCHE-3157608,ROCHE,,54,YR,,M,Y,,,20220815,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,212113091,OT,,,,,,,,,212113091,1,Bipolar disorder
21211499,212114991,1,I,,20220803,20220815,20220815,EXP,,UG-MYLANLABS-2022M1086623,MYLAN,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica. 2020;109:2706-16",9,YR,,M,Y,,,20220815,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,212114991,OT,,,,,,,,,212114991,1,HIV infection
21213971,212139711,1,I,,20220803,20220816,20220816,EXP,,UG-AUROBINDO-AUR-APL-2022-031760,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica.. 2020;109:2706-16",3,YR,,,Y,,,20220816,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,212139711,OT,,,,,,,,,212139711,1,HIV infection
21213977,212139771,1,I,,20220803,20220816,20220816,EXP,,UG-AUROBINDO-AUR-APL-2022-031765,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children.. Acta Paediatrica... 2020;109:2706-16",3,YR,,,Y,,,20220816,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,212139771,OT,,,,,,,,,212139771,1,HIV infection
21213995,212139951,1,I,,20220803,20220816,20220816,EXP,,SE-AUROBINDO-AUR-APL-2022-031768,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica. 2020;109:2706-16",9,YR,,,Y,,,20220816,,HP,SE,UG,EFAVIRENZ,Pathogen resistance,212139951,OT,,,,,,,,,212139951,1,HIV infection
21214005,212140052,2,F,,20220816,20220816,20220824,EXP,,UG-AUROBINDO-AUR-APL-2022-031771,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica.. Acta Paediatrica.. 2020;109:2706-16",5,YR,,,Y,,,20220824,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,212140052,OT,,,,,,,,,212140052,1,HIV infection
21214633,212146331,1,I,,20220803,20220816,20220816,EXP,,SE-AUROBINDO-AUR-APL-2022-031763,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al... Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children.. Acta Paediatrica.. 2020;109:2706-16.",5,YR,,,Y,,,20220816,,HP,SE,UG,EFAVIRENZ,Pathogen resistance,212146331,OT,,,,,,,,,212146331,1,HIV infection
21214650,212146501,1,I,,20220803,20220816,20220816,EXP,,SE-AUROBINDO-AUR-APL-2022-031769,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al.. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children. Acta Paediatrica. 2020;109:2706-16",4,YR,,,Y,,,20220816,,HP,SE,UG,EFAVIRENZ,Pathogen resistance,212146501,OT,,,,,,,,,212146501,1,HIV infection
21214670,212146701,1,I,,20220803,20220816,20220816,EXP,,UG-AUROBINDO-AUR-APL-2022-031767,AUROBINDO,"Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Rubin J, Eriksen J, et al.. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-na?ve Ugandan children.. Acta Paediatrica. 2020;109:2706-16",7,YR,,,Y,,,20220816,,HP,UG,UG,EFAVIRENZ,Pathogen resistance,212146701,OT,,,,,,,,,212146701,1,HIV infection
21217347,212173471,1,I,20220101,20220808,20220816,20220816,PER,,US-SA-2022SA332953,SANOFI AVENTIS,,56,YR,A,F,Y,,,20220816,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Injection site pain,,,,,212173471,1,20220427,,,,212173471,1,Dermatitis atopic
21217772,212177722,2,F,,20220823,20220816,20220901,EXP,,ES-TEVA-2022-ES-2064395,TEVA,,,,,M,Y,,,20220901,,HP,ES,ES,EFAVIRENZ,Cushing's syndrome;Drug ineffective;Drug interaction;Tertiary adrenal insufficiency,212177722,OT,,,212177722,11,,,5,YR,212177722,1,HIV infection
21218215,212182151,1,I,,20220808,20220816,20220816,EXP,,CA-AstraZeneca-2022A285586,ASTRAZENECA,,,,,M,Y,,,20220816,,MD,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,212182151,HO,,,,,,,,,212182151,1,Product used for unknown indication
21220297,212202974,4,F,20100629,20220913,20220817,20220927,EXP,,GB-AUROBINDO-AUR-APL-2018-044992,AUROBINDO,,43,YR,,F,Y,,,20220927,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,212202974,OT,,,212202974,1,20171006,20180205,4,MON,212202974,1,HIV infection
21222657,212226571,1,I,,20220809,20220817,20220817,EXP,,CA-AstraZeneca-2022A287741,ASTRAZENECA,,54,YR,,M,Y,,,20220817,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,212226571,OT,,,,,,,,,212226571,1,Bipolar disorder
21222931,212229311,1,I,,20220812,20220817,20220817,EXP,,CA-AstraZeneca-2022A287709,ASTRAZENECA,,44,YR,,M,Y,,,20220817,,HP,CA,,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,212229311,HO,,,,,,,,,212229311,1,Bipolar disorder
21227585,212275851,1,I,,20220815,20220818,20220818,EXP,,IN-GILEAD-2022-0594043,GILEAD,"Yadav R, Chopra K, Jaiswal N. Study of impact of WHO option B+ on maternal and perinatal outcome in HIV-positive women delivering at a tertiary care hospital, Delhi. Indian J Sex Transm Dis AIDS.. 2022;43(1):90-91. doi:10.4103/ijstd.ijstd_24_21",,,A,F,Y,,,20220818,,HP,IN,IN,EFAVIRENZ,Ectopic pregnancy;Maternal exposure during pregnancy,212275851,OT,,,,,,,,,212275851,1,HIV infection
21227749,212277491,1,I,,20220815,20220818,20220818,EXP,,IN-GILEAD-2022-0593738,GILEAD,"Yadav R, Chopra K, Jaiswal N. Study of impact of WHO option B+ on maternal and perinatal outcome in HIV-positive women delivering at a tertiary care hospital, Delhi. Indian J Sex Transm Dis AIDS.. 2022;43(1):90-91. doi:10.4103/ijstd.ijstd_24_21",,,A,F,Y,,,20220818,,HP,IN,IN,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,212277491,OT,,,,,,,,,212277491,1,HIV infection
21229955,212299551,1,I,,20220812,20220818,20220818,EXP,,IN-GSK-IN2022GSK118227,GLAXOSMITHKLINE,,,,,,Y,,,20220818,,MD,IN,IN,EFAVIRENZ,Apoptosis;Drug eruption;Erythema;Immune reconstitution inflammatory syndrome;Lichenoid keratosis;Lymphadenopathy;Lymphocytic infiltration;Non-scarring alopecia;Parakeratosis;Rash;Secondary syphilis;Skin exfoliation;Skin hyperpigmentation;Skin lesion;Skin plaque,212299551,OT,,,,,,,,,212299551,1,HIV infection
21229958,212299581,1,I,,20220812,20220818,20220818,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2022GSK118227,VIIV,,,,,,Y,,,20220818,,MD,IN,IN,EFAVIRENZ,Apoptosis;Drug eruption;Erythema;Immune reconstitution inflammatory syndrome;Lichenoid keratosis;Lymphadenopathy;Lymphocytic infiltration;Non-scarring alopecia;Parakeratosis;Rash;Secondary syphilis;Skin exfoliation;Skin hyperpigmentation;Skin lesion;Skin plaque,212299581,OT,,,,,,,,,212299581,1,HIV infection
21230236,212302361,1,I,,20220815,20220818,20220818,EXP,,IN-GILEAD-2022-0593992,GILEAD,"Pangti, R; Bhari, N;  Dhawan, B; Gupta, S.. Lichenoid secondary syphilis as immune reconstitution inflammatory syndrome with mixed etiology genital ulcer in a human immunodeficiency viruspositive patient.. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43 (1):86-87",32,YR,A,M,Y,,,20220818,,MD,IN,IN,EFAVIRENZ,Drug eruption;Immune reconstitution inflammatory syndrome;Secondary syphilis,212302361,OT,,,,,,,,,212302361,1,Product used for unknown indication
21233347,212333471,1,I,20170530,20220817,20220819,20220819,EXP,,ZA-GILEAD-2022-0594267,GILEAD,,30,YR,A,F,Y,,,20220819,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,212333471,OT,,,212333471,1,20170224,,,,212333471,1,HIV infection
21233510,212335101,1,I,,20220815,20220819,20220819,EXP,,CA-AstraZeneca-2022A289166,ASTRAZENECA,,54,YR,,M,Y,,,20220819,,MD,CA,,SUSTIVA,Depression;Drug interaction,212335101,OT,,,,,,,,,212335101,1,Product used for unknown indication
21234412,212344121,1,I,,20220812,20220820,20220820,EXP,,IT-STRIDES ARCOLAB LIMITED-2022SP010540,STRIDES,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract. 2021;11(5):E627-E633",71,YR,,M,Y,,,20220820,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,212344121,OT,,,,,,,,,212344121,1,HIV infection
21234498,212344981,1,I,,20220809,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032494,AUROBINDO,,,,,M,Y,,,20220820,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,212344981,HO,,,,,,,,,212344981,1,Product used for unknown indication
21236182,212361821,1,I,,20220809,20220822,20220822,EXP,,CA-AUROBINDO-AUR-APL-2022-033204,AUROBINDO,,54,YR,,M,Y,,,20220822,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,212361821,OT,,,,,,,,,212361821,1,HIV infection
21236359,212363591,1,I,,20220809,20220822,20220822,EXP,,CA-AUROBINDO-AUR-APL-2022-033209,AUROBINDO,,54,YR,,M,Y,,,20220822,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,212363591,OT,,,,,,,,,212363591,1,HIV infection
21238262,212382621,1,I,,20220812,20220822,20220822,EXP,,IT-MYLANLABS-2022M1087630,MYLAN,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract 2021;11(5):E627-E633.",71,YR,,M,Y,,,20220822,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,212382621,OT,,,,,,,,,212382621,1,HIV infection
21239988,212399881,1,I,20170822,20220816,20220822,20220822,EXP,,ZA-MYLANLABS-2022M1087832,MYLAN,,30,YR,,F,Y,,,20220822,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous,212399881,OT,,,212399881,1,20170224,,,,212399881,1,HIV infection
21242637,212426371,1,I,,20220812,20220823,20220823,EXP,,IN-CIPLA LTD.-2022IN05058,CIPLA,"Harjani RG, Hinduja RH, Iyer AK.. Intracranial lymphoma in human immunodeficiency virus-infected patients: A diagnostic dilemma?. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43:1:82 to 84",42,YR,,M,Y,,,20220823,,MD,IN,IN,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance,212426371,OT,,,,,,,,,212426371,1,HIV infection
21242990,212429901,1,I,,20220817,20220823,20220823,EXP,,IN-MYLANLABS-2022M1088396,MYLAN,"Pangti R, Gupta S, Bhari N, Dhawan B, Gupta S. Lichenoid secondary syphilis as immune reconstitution inflammatory syndrome with mixed etiology genital ulcer in a human immunodeficiency virus-positive patient. India-J-Sex-Transm-Dis 2022;43(1):86-87.",32,YR,,M,Y,,,20220823,,MD,IN,IN,EFAVIRENZ,Genital herpes;Herpes simplex;Immune reconstitution inflammatory syndrome;Lichenoid keratosis;Paradoxical drug reaction;Syphilis,212429901,OT,,,,,,,,,212429901,1,HIV infection
21244489,212444891,1,I,,20220817,20220823,20220823,EXP,,CN-GSK-CN2022GSK119896,GLAXOSMITHKLINE,,,,,,Y,,,20220823,,HP,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance,212444891,OT,,,212444891,1,20190629,,,,212444891,1,HIV infection
21244491,212444911,1,I,,20220817,20220823,20220823,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK119896,VIIV,,,,,,Y,,,20220823,,HP,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance,212444911,OT,,,212444911,1,20190629,,,,212444911,1,HIV infection
21253744,212537441,1,I,,20220715,20220825,20220825,EXP,,ES-GLAXOSMITHKLINE-ESCH2022GSK029857,GLAXOSMITHKLINE,,,,,,Y,,,20220825,,HP,ES,ES,EFAVIRENZ,Adrenal insufficiency;Asthenia;Contusion;Cushing's syndrome;Cushingoid;Drug interaction;Exercise tolerance decreased;Fat tissue increased;Virologic failure,212537441,OT,,,,,,,,,212537441,1,Asthma
21255189,212551891,1,I,,20220819,20220825,20220825,EXP,,GB-MYLANLABS-2022M1088443,MYLAN,,,,,M,Y,,,20220825,,HP,GB,GB,EFAVIRENZ,Hospitalisation,212551891,HO,,,,,,,,,212551891,1,Product used for unknown indication
21258149,212581491,1,I,,20220815,20220826,20220826,EXP,,IN-CIPLA LTD.-2022IN05113,CIPLA,"Pangti R, Gupta S, Gupta S, Bhari N, Dhawan B.. Lichenoid secondary syphilis as immune reconstitution inflammatory syndrome with mixed etiology genital ulcer in a human immunodeficiency virus-positive patient. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43:86 to 87",32,YR,,M,Y,,,20220826,,HP,IN,IN,EFAVIRENZ,Genital herpes;Immune reconstitution inflammatory syndrome;Lichenoid keratosis;Secondary syphilis,212581491,OT,,,,,,,,,212581491,1,HIV infection
21259121,212591211,1,I,,20220815,20220826,20220826,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022123308,VIIV,,,,,,Y,,,20220826,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,212591211,OT,,,,,,,,,212591211,1,HIV infection
21259140,212591401,1,I,,20220815,20220826,20220826,EXP,,CN-GSK-CN2022123308,GLAXOSMITHKLINE,,,,,,Y,,,20220826,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,212591401,OT,,,,,,,,,212591401,1,HIV infection
21260524,212605241,1,I,,20220328,20220826,20220826,EXP,,AL-GSK-AL2022GSK122512,GLAXOSMITHKLINE,"Muco E, Karruli A, Hoxha N, Hoxhaj A, Kokici M. Visceral Leishmaniasis and Herpes Zoster as a Component of Syndrome of Immune Reconstitution Inflammatory Syndrome in an HIV-Positive Patient. Case reports in infectious diseases. 2022;2022",,,,,Y,,,20220826,,HP,AL,AL,EFAVIRENZ,Abdominal distension;Blister;Fatigue;Hepatomegaly;Hepatosplenomegaly;Herpes zoster;Hyperhidrosis;Immune reconstitution inflammatory syndrome;Lethargy;Lymphadenopathy;Pancytopenia;Pustule;Pyrexia;Rash maculo-papular;Scab;Skin lesion;Splenomegaly;Visceral leishmaniasis;Weight decreased,212605241,OT,,,,,,,,,212605241,1,HIV infection CDC category C
21260528,212605281,1,I,,20220328,20220826,20220826,EXP,,AL-VIIV HEALTHCARE LIMITED-AL2022GSK122512,VIIV,"Muco E, Karruli A, Hoxha N, Hoxhaj A, Kokici M. Visceral Leishmaniasis and Herpes Zoster as a Component of Syndrome of Immune Reconstitution Inflammatory Syndrome in an HIV-Positive Patient. Case reports in infectious diseases. 2022;2022",,,,,Y,,,20220826,,HP,AL,AL,EFAVIRENZ,Abdominal distension;Blister;Fatigue;Hepatomegaly;Hepatosplenomegaly;Herpes zoster;Hyperhidrosis;Immune reconstitution inflammatory syndrome;Lethargy;Lymphadenopathy;Pancytopenia;Pustule;Pyrexia;Rash maculo-papular;Scab;Skin lesion;Splenomegaly;Visceral leishmaniasis;Weight decreased,212605281,OT,,,,,,,,,212605281,1,HIV infection CDC category C
21261157,212611571,1,I,,20220825,20220826,20220826,EXP,,CA-BAUSCH-BL-2022-020974,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220826,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,212611571,OT,,,,,,,,,212611571,1,Bipolar disorder
21264010,212640101,1,I,,20220819,20220829,20220829,EXP,,FR-AUROBINDO-AUR-APL-2022-033883,AUROBINDO,,,,A,M,Y,,,20220829,,MD,FR,FR,SUSTIVA,Virologic failure,212640101,OT,,,212640101,1,20060615,20090615,3,YR,212640101,1,HIV infection
21264035,212640351,1,I,,20220819,20220829,20220829,EXP,,ES-AUROBINDO-AUR-APL-2022-033954,AUROBINDO,"Gomez AS, Garcia MJA, Maria Rafael Saponi Cortes J, Ruiz CM.. Cushing^s syndrome secondary to inhaled fluticasone.. Endocrinol-Diabetes-Nutr. 2022;69(6):442-444",,,,M,Y,,,20220829,,HP,ES,ES,EFAVIRENZ,Cushing's syndrome;Drug ineffective;Drug interaction;Tertiary adrenal insufficiency,212640351,OT,,,212640351,14,,,5,YR,212640351,1,HIV infection
21264121,212641211,1,I,20170822,20220816,20220829,20220829,EXP,,ZA-AUROBINDO-AUR-APL-2022-033761,AUROBINDO,,30,YR,,F,Y,,,20220829,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,212641211,OT,,,212641211,1,20170224,,,,212641211,1,HIV infection
21264327,212643271,1,I,,20220817,20220829,20220829,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-2022-092170,BRISTOL MYERS SQUIBB,"Gupta S, Gupta S, Bhari N, Dhawan B, Pangti R. Lichenoid secondary syphilis as immune reconstitution inflammatory syndrome with mixed etiology genital ulcer in a human immunodeficiency virus-positive patient. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022; 43(1): 86-7. 10.4103/ijstd.ijstd_110_20",32,YR,A,M,Y,,,20220829,,HP,IN,IN,EFAVIRENZ,Genital herpes;Lichenoid keratosis;Secondary syphilis,212643271,OT,,,,,,,,,212643271,1,HIV test positive
21264423,212644231,1,I,20170822,20220816,20220829,20220829,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-093269,BRISTOL MYERS SQUIBB,,30,YR,A,F,Y,,,20220829,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Prescribed overdose,212644231,OT,,,212644231,1,20170224,,,,212644231,1,HIV infection
21265092,212650921,1,I,20170822,20220817,20220829,20220829,EXP,,ZA-CIPLA LTD.-2022ZA05102,CIPLA,,30,YR,,F,Y,,,20220829,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,212650921,OT,,,212650921,1,20170224,,,,212650921,1,HIV infection
21265636,212656361,1,I,,20220823,20220829,20220829,EXP,,NA-MYLANLABS-2022M1089621,MYLAN,"Kakubu MAM, Kalonji M, Katoto PDMC. A Case Report of Multiclass HIV Drug-Resistance After an Inappropriate Switch of ARVs with Persistent Unsuppressed Viral Load. J-Int-Assoc-Provid-AIDS-Care 2022;null:null.",48,YR,,F,Y,,,20220829,,MD,,,EFAVIRENZ,Drug resistance,212656361,OT,,,212656361,1,200906,201404,,,212656361,1,HIV test positive
21266482,212664821,1,I,,20220817,20220829,20220829,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022036934,MACLEODS,,,,,,Y,,,20220829,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,212664821,OT,,,212664821,1,20170224,,,,212664821,1,HIV infection
21267365,212673651,1,I,,20220823,20220829,20220829,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2022EME122837,VIIV,,,,,,Y,,,20220829,,HP,GB,GB,EFAVIRENZ,Hospitalisation,212673651,HO,,,,,,,,,212673651,1,Product used for unknown indication
21267387,212673871,1,I,,20220823,20220829,20220829,EXP,,GB-GSK-GB2022EME122837,GLAXOSMITHKLINE,,,,,,Y,,,20220829,,HP,GB,GB,EFAVIRENZ,Hospitalisation,212673871,HO,,,,,,,,,212673871,1,Product used for unknown indication
21269614,212696141,1,I,,20220825,20220830,20220830,EXP,,CA-BAUSCH-BL-2022-021010,BAUSCH AND LOMB,,,,,M,Y,,,20220830,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,212696141,OT,,,,,,,,,212696141,1,Product used for unknown indication
21269618,212696181,1,I,,20220825,20220830,20220830,EXP,,CA-BAUSCH-BL-2022-020997,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220830,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,212696181,OT,,,,,,,,,212696181,1,Bipolar disorder
21280548,212805481,1,I,,20220825,20220901,20220901,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK125136,VIIV,,,,,,Y,,,20220901,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,212805481,OT,,,,,,,,,212805481,1,Product used for unknown indication
21280549,212805491,1,I,,20220825,20220901,20220901,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK125134,VIIV,,,,,,Y,,,20220901,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,212805491,OT,,,,,,,,,212805491,1,HIV infection
21280558,212805581,1,I,,20220825,20220901,20220901,EXP,,CA-GSK-CA2022GSK125136,GLAXOSMITHKLINE,,,,,,Y,,,20220901,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,212805581,HO,,,,,,,,,212805581,1,Product used for unknown indication
21280563,212805631,1,I,,20220825,20220901,20220901,EXP,,CA-GSK-CA2022GSK125134,GLAXOSMITHKLINE,,,,,,Y,,,20220901,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,212805631,OT,,,,,,,,,212805631,1,HIV infection
21280635,212806351,1,I,,20220825,20220901,20220901,EXP,,CA-GSK-CA2019GSK240956,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20220901,,MD,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,212806351,DE,,,212806351,6,20070620,,,,212806351,1,Depression
21280873,212808731,1,I,20210927,20220825,20220901,20220901,EXP,,GB-GILEAD-2022-0595790,GILEAD,,31,YR,A,F,Y,,,20220901,,HP,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,212808731,OT,,,,,,,,,212808731,1,HIV infection
21281188,212811881,1,I,,20220823,20220901,20220901,EXP,,IN-MYLANLABS-2022M1090014,MYLAN,"Patra PC, Samal P, Bhola RK, Pradhan S. An event of Evans even in HIV. India-J-Sex-Transm-Dis 2022;43(1):64-66.",32,YR,,F,Y,,,20220901,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Evans syndrome,212811881,HO,,,212811881,2,,,3,DAY,212811881,1,Antiretroviral therapy
21281891,212818911,1,I,,20220822,20220901,20220901,EXP,,IT-TEVA-2022-IT-2068488,TEVA,,71,YR,E,M,Y,,,20220901,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,212818911,OT,,,,,,,,,212818911,1,HIV infection
21285604,212856042,2,F,20180112,20220901,20220902,20220906,EXP,,GB-AUROBINDO-AUR-APL-2022-030023,AUROBINDO,,,,,,Y,,,20220906,,MD,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,212856042,CA,,,212856042,3,20100610,,,,212856042,1,Product used for unknown indication
21285914,212859141,1,I,20220628,20220825,20220902,20220902,PER,,US-VIIV HEALTHCARE LIMITED-US2022AMR124211,VIIV,,46,YR,,M,Y,,,20220902,,HP,US,US,SUSTIVA,Viral load increased,,,,,212859141,1,20220421,,,,212859141,1,HIV infection CDC category B
21290056,212900561,1,I,20020201,20220826,20220902,20220902,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2022EME124553,VIIV,"Nabiullina DR, Mazus AI, Litivinova NG, Khamatova AA, Nagibina MV, Chebotareva TA, et.al.. Practical aspects of human immunodeficiency virus multiresistance in modern clinical practice. Epidemiology and Infectious Diseases. 2021;26 (3):113-126",,,,,Y,,,20220902,,MD,RU,RU,EFAVIRENZ,Drug ineffective;Hepatitis toxic;Nausea;Pathogen resistance;Virologic failure;Vomiting,212900561,OT,,,212900561,1,1999,200202,4,MON,212900561,1,HIV infection
21290057,212900571,1,I,20020201,20220826,20220902,20220902,EXP,,RU-GSK-RU2022EME124553,GLAXOSMITHKLINE,"Nabiullina DR, Mazus AI, Litivinova NG, Khamatova AA, Nagibina MV, Chebotareva TA, et.al.. Practical aspects of human immunodeficiency virus multiresistance in modern clinical practice. Epidemiology and Infectious Diseases. 2021;26 (3):113-126",,,,,Y,,,20220902,,MD,RU,RU,EFAVIRENZ,Drug ineffective;Hepatitis toxic;Nausea;Pathogen resistance;Virologic failure;Vomiting,212900571,OT,,,212900571,1,1999,200202,4,MON,212900571,1,HIV infection
21290630,212906301,1,I,,20220823,20220903,20220903,EXP,,IT-AUROBINDO-AUR-APL-2022-034347,AUROBINDO,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al.. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract. 2021;11(5):E627-E633.",71,YR,,M,Y,,,20220903,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,212906301,OT,,,,,,,,,212906301,1,HIV infection
21290780,212907801,1,I,,20220822,20220903,20220903,EXP,,IN-HETERO-HET2022IN02049,HETERO,"Pangti R, Gupta S, Bhari N, Dhawan B, Gupta S. Lichenoid secondary syphilis as immune reconstitution inflammatory syndrome with mixed etiology genital ulcer in a human immunodeficiency virus?positive patient. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43(1):86-87",32,YR,,M,Y,,,20220903,,HP,IN,IN,EFAVIRENZ,Genital herpes;Immune reconstitution inflammatory syndrome;Secondary syphilis,212907801,OT,,,,,,,,,212907801,1,HIV infection
21291596,212915961,1,I,20220628,20220825,20220903,20220903,PER,,US-JNJFOC-20220904524,JOHNSON AND JOHNSON,,46,YR,A,M,Y,,,20220903,,HP,US,US,SUSTIVA,Viral load increased,,,,,212915961,1,20220421,,,,212915961,1,HIV infection CDC category B
21293953,212939531,1,I,,20220825,20220905,20220905,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK124460,VIIV,,,,,,Y,,,20220905,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,212939531,OT,,,,,,,,,212939531,1,HIV infection
21293975,212939751,1,I,,20220825,20220905,20220905,EXP,,CA-GSK-CA2022GSK124460,GLAXOSMITHKLINE,,,,,,Y,,,20220905,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,212939751,OT,,,,,,,,,212939751,1,HIV infection
21297068,212970681,1,I,,20220831,20220906,20220906,EXP,,CA-AstraZeneca-2022A305013,ASTRAZENECA,,54,YR,,M,Y,,,20220906,,MD,CA,,SUSTIVA,Depression;Drug interaction,212970681,OT,,,,,,,,,212970681,1,Product used for unknown indication
21301279,213012791,1,I,,20220831,20220907,20220907,EXP,,CA-AstraZeneca-2022A305019,ASTRAZENECA,,54,YR,,M,Y,,,20220907,,MD,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,213012791,OT,,,,,,,,,213012791,1,Bipolar disorder
21303387,213033871,1,I,,20220826,20220907,20220907,EXP,,CA-MYLANLABS-2022M1091917,MYLAN,,,,,M,Y,,,20220907,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,213033871,HO,,,,,,,,,213033871,1,Product used for unknown indication
21306338,213063382,2,F,20210618,20220901,20220908,20220915,EXP,,ES-AUROBINDO-AUR-APL-2022-032121,AUROBINDO,,22,YR,,M,Y,,,20220915,,MD,ES,ES,EFAVIRENZ,Off label use;Treatment noncompliance;Virologic failure,213063382,OT,,,213063382,2,20210618,20220218,246,DAY,213063382,1,HIV infection
21308221,213082211,1,I,,20220831,20220908,20220908,EXP,,CA-AstraZeneca-2022A304932,ASTRAZENECA,,,,,M,Y,,,20220908,,MD,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,213082211,HO,,,,,,,,,213082211,1,Product used for unknown indication
21308901,213089011,1,I,20210927,20220904,20220908,20220908,EXP,,GB-MYLANLABS-2022M1091635,MYLAN,,31,YR,,F,Y,,,20220908,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,213089011,OT,,,,,,,,,213089011,1,HIV infection
21320678,213206782,2,F,20190101,20200323,20220912,20220912,EXP,,PG-JNJFOC-20200338048,JOHNSON AND JOHNSON,,25,YR,A,F,Y,56,KG,20220912,,MD,PG,PG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Eosinophilia;Exposure during pregnancy;Foetal death;Hypomagnesaemia;Inappropriate schedule of product administration;Intentional product use issue;Liver function test increased;Off label use;Postpartum haemorrhage,213206782,OT,,,213206782,1,20190328,20190925,181,DAY,213206782,1,Tuberculosis
21327823,213278231,1,I,20220713,,20220912,20220912,DIR,631092,,FDA-CTU,,54,YR,,M,N,51.75,KG,20220912,N,CN,US,,SUSTIVA,Ejaculation disorder,213278231,OT,213278231,CSM,213278231,1,20220708,20220713,,,213278231,1,COVID-19
21332236,213322361,1,I,,20220901,20220914,20220914,EXP,,IN-Appco Pharma LLC-2132840,APPCO PHARMA,"Patra P, Samal P, Bhola R, Pradhan S. An event of Evans even in HIV. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022 JUN 07;43(1):64-6. DOI: 10.4103/ijstd.ijstd_113_20",32,YR,,F,Y,,,20220914,,MD,IN,IN,EFAVIRENZ,Evans syndrome,213322361,OT,,,,,,,,,213322361,1,HIV infection
21333037,213330371,1,I,20150101,20220907,20220914,20220914,EXP,,PT-GSK-PT2022EME129711,GLAXOSMITHKLINE,,,,,,Y,,,20220914,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213330371,OT,,,213330371,1,201504,2015,,,213330371,1,Antiretroviral therapy
21333097,213330971,1,I,20150101,20220907,20220914,20220914,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022EME129711,VIIV,,,,,,Y,,,20220914,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213330971,OT,,,213330971,1,201504,2015,,,213330971,1,Antiretroviral therapy
21334238,213342381,1,I,20210927,20220904,20220914,20220914,EXP,,GB-TEVA-2022-GB-2071405,TEVA,,31,YR,A,F,Y,,,20220914,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,213342381,OT,,,,,,,,,213342381,1,HIV infection
21335490,213354901,1,I,20210927,20220904,20220915,20220915,EXP,,GB-AUROBINDO-AUR-APL-2022-035997,AUROBINDO,,31,YR,,F,Y,,,20220915,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,213354901,OT,,,,,,,,,213354901,1,HIV infection
21336494,213364941,1,I,,20220904,20220915,20220915,EXP,,TH-HETERO-HET2022TH02235,HETERO,"Wongjirattikarn R, Sriaram A, Pemcharoen J, Asawanonda P, Boontaveeyuwat E. Anti-retroviral drugs induced Photosensitivity may be Two culprits in Mixed formulation, a case report and literature review. Photodiagnosis and Photodynamic Therapy. 2022",63,YR,,F,Y,,,20220915,,MD,TH,TH,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Photosensitivity reaction;Pseudoporphyria,213364941,OT,,,,,,,,,213364941,1,Asymptomatic HIV infection
21336659,213366591,1,I,,20220902,20220915,20220915,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022037174,MACLEODS,"Isaacs T, Ngwanya MR, Dlamini S, Lehloenya RJ. Annular erythema and photosensitivity as manifestations of efavirenz-induced cutaneous reactions: a review of five consecutive cases. Journal of Antimicrobial Chemotherapy. 2013;68(12):2871-2874",,,,,Y,,,20220915,,HP,ZA,ZA,EFAVIRENZ,Erythema annulare;Maternal exposure during pregnancy;Photosensitivity reaction,213366591,HO,,,,,,,,,213366591,1,HIV infection
21337663,213376631,1,I,,20220911,20220915,20220915,EXP,,IN-GILEAD-2022-0597688,GILEAD,"Sarkar A, Rohilla M, Kumari S. Concurrence of glucose-6-phosphate dehydrogenase deficiency in pregnancy. Journal of Obstetrics and Gynaecolog. 2022;42(5):747-750. doi:10.1080/01443615.2021.2024157",,,N,,Y,,,20220915,,HP,IN,IN,EFAVIRENZ,Death neonatal;Foetal exposure during pregnancy;Neural tube defect,213376631,DE,,,,,,,,,213376631,1,HIV infection
21338119,213381191,1,I,,20220908,20220915,20220915,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2022GSK131647,VIIV,"Sarkar A, Rohilla M, Kumari S. Concurrence of glucose-6-phosphate dehydrogenase deficiency in pregnancy. Journal of Obstetrics and Gynaecology. 2022;42(5):747-750",,,,,Y,,,20220915,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,213381191,CA,,,,,,,,,213381191,1,HIV infection
21338120,213381201,1,I,,20220908,20220915,20220915,EXP,,IN-GSK-IN2022GSK131647,GLAXOSMITHKLINE,"Sarkar A, Rohilla M, Kumari S. Concurrence of glucose-6-phosphate dehydrogenase deficiency in pregnancy. Journal of Obstetrics and Gynaecology. 2022;42(5):747-750",,,,,Y,,,20220915,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,213381201,CA,,,,,,,,,213381201,1,HIV infection
21342601,213426011,1,I,20210927,20220904,20220916,20220916,EXP,,GB-MACLEODS PHARMA UK LTD-MAC2022037190,MACLEODS,,,,,,Y,,,20220916,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,213426011,OT,,,,,,,,,213426011,1,HIV infection
21349328,213493281,1,I,,20220913,20220919,20220919,EXP,,CA-ROCHE-3178797,ROCHE,,54,YR,,M,Y,,,20220919,,HP,CA,,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,213493281,DE,,,,,,,,,213493281,1,Bipolar disorder
21350279,213502791,1,I,,20220916,20220919,20220919,EXP,,IT-GSK-IT2022133577,GLAXOSMITHKLINE,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al.. Alzheimer Dementia in People Living With HIV.. Neurol-Clin-Pract. 2021;11(5):E627-E633",,,,,Y,,,20220919,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,213502791,OT,,,,,,,,,213502791,1,HIV infection
21350280,213502801,1,I,,20220916,20220919,20220919,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2022133577,VIIV,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al.. Alzheimer Dementia in People Living With HIV.. Neurol-Clin-Pract. 2021;11(5):E627-E633",,,,,Y,,,20220919,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,213502801,OT,,,,,,,,,213502801,1,HIV infection
21350741,213507411,1,I,,20220908,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107980,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213507411,OT,,,,,,,,,213507411,1,HIV test positive
21350742,213507421,1,I,,20220908,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107982,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213507421,HO,,,,,,,,,213507421,1,HIV test positive
21350786,213507861,1,I,,20220908,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107983,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213507861,HO,,,,,,,,,213507861,1,HIV test positive
21350787,213507871,1,I,,20220908,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107985,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213507871,HO,,,,,,,,,213507871,1,HIV test positive
21350827,213508271,1,I,,20220912,20220919,20220919,EXP,,EG-VIIV HEALTHCARE LIMITED-EG2022GSK134151,VIIV,"Gaballah A, Ghazal A, Metwally D, Emad R, Essam G, Attia NM et al. Mutation patterns, cross resistance and virological failure among HIV type-1 patients in Alexandria, Egypt. Future Virology. 2022;17(7):441-454",,,,,Y,,,20220919,,HP,EG,EG,EFAVIRENZ,Pathogen resistance;Viral mutation identified,213508271,OT,,,,,,,,,213508271,1,HIV infection
21350903,213509031,1,I,,20220912,20220919,20220919,EXP,,EG-VIIV HEALTHCARE LIMITED-EG2022GSK134150,VIIV,"Gaballah A, Ghazal A, Metwally D, Emad R, Essam G, Attia NM et al. Mutation patterns, cross resistance and virological failure among HIV type-1 patients in Alexandria, Egypt. Future Virology. 2022;17(7):441-454",,,,,Y,,,20220919,,HP,EG,EG,EFAVIRENZ,Pathogen resistance;Viral mutation identified,213509031,OT,,,,,,,,,213509031,1,HIV infection
21350943,213509431,1,I,,20220908,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107978,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213509431,HO,,,,,,,,,213509431,1,HIV test positive
21350944,213509441,1,I,,20220908,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107979,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213509441,HO,,,,,,,,,213509441,1,HIV test positive
21350958,213509581,1,I,,20220908,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107975,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220919,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213509581,HO,,,,,,,,,213509581,1,HIV test positive
21351716,213517161,1,I,,20220908,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-107987,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220920,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213517161,HO,,,,,,,,,213517161,1,HIV test positive
21351747,213517471,1,I,,20220908,20220919,20220919,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-2022-055611,BRISTOL MYERS SQUIBB,"Rensburg R, Nightingale S, Brey N, Albertyn C, Kellermann T, Taljaard J. et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome(lens). Topics in Antiviral Medicine. 2022; 30(1): 149.",,,,F,Y,49.9,KG,20220920,,HP,ZA,ZA,EFAVIRENZ,Neurotoxicity,213517471,HO,,,,,,,,,213517471,1,HIV test positive
21352750,213527501,1,I,,20220914,20220920,20220920,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-107110,BRISTOL MYERS SQUIBB,,52,YR,A,M,Y,,,20220920,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,213527501,OT,,,,,,,,,213527501,1,HIV infection
21354782,213547821,1,I,20150101,20220915,20220920,20220920,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-107544,BRISTOL MYERS SQUIBB,,45,YR,A,M,Y,,,20220920,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213547821,OT,,,213547821,1,200307,201511,6,MON,213547821,1,Antiretroviral therapy
21356659,213566591,1,I,20100101,20220915,20220920,20220920,PER,,US-GILEAD-2022-0598029,GILEAD,,48,YR,A,M,Y,,,20220920,,MD,US,US,EFAVIRENZ,Drug intolerance;Genotype drug resistance test positive;Treatment failure;Vomiting,,,,,,,,,,,213566591,1,HIV infection
21364311,213643111,1,I,,20220915,20220922,20220922,EXP,,DK-MYLANLABS-2022M1095642,MYLAN,"Mens H, Fjordside L, Fonager J, Gerstoft J. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infect-Dis-Rep 2022;14(4):501-504.",50,YR,,M,Y,,,20220922,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance,213643111,OT,,,,,,,,,213643111,1,HIV infection
21366081,213660811,1,I,,20220919,20220922,20220922,PER,,US-GILEAD-2022-0598643,GILEAD,,,,,M,Y,,,20220922,,CN,US,US,EFAVIRENZ,Rash,,,,,,,,,,,213660811,1,Product used for unknown indication
21366083,213660832,2,F,,20220922,20220922,20220926,EXP,,IT-GILEAD-2022-0598645,GILEAD,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract. 2021;11(5):E627-E633",71,YR,E,M,Y,,,20220926,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,213660832,OT,,,,,,,,,213660832,1,HIV infection
21367727,213677271,1,I,,20220913,20220923,20220923,EXP,,CA-TEVA-2022-CA-2074579,TEVA,,54,YR,A,M,Y,,,20220923,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,213677271,OT,,,,,,,,,213677271,1,HIV infection
21368218,213682181,1,I,,20220913,20220923,20220923,EXP,,CA-TEVA-2022-CA-2074597,TEVA,,54,YR,A,M,Y,,,20220923,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,213682181,OT,,,,,,,,,213682181,1,HIV infection
21368770,213687701,1,I,,20220914,20220923,20220923,EXP,,CA-009507513-2209CAN005857,MERCK,,54,YR,,M,Y,,,20220923,,HP,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,213687701,OT,,,213687701,11,,,2,DAY,213687701,1,HIV infection
21369715,213697151,1,I,,20220915,20220923,20220923,EXP,,CA-APOTEX-2022AP013130,APOTEX,,54,YR,,M,Y,,,20220923,,HP,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,213697151,OT,,,213697151,6,,,2,DAY,213697151,1,Psychotic disorder
21370032,213700321,1,I,,20220913,20220923,20220923,EXP,,CA-TEVA-2022-CA-2074575,TEVA,,,,,M,Y,,,20220923,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,213700321,HO,,,,,,,,,213700321,1,Product used for unknown indication
21373970,213739701,1,I,20150101,20220919,20220926,20220926,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192778",BOEHRINGER INGELHEIM,,45,YR,A,M,Y,,,20220926,,CN,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213739701,OT,,,213739701,1,200404,201504,11,YR,213739701,1,Antiretroviral therapy
21376451,213764512,2,F,20150815,20220920,20220926,20220926,EXP,FR-EMA-DD-20220914-116353-132430,FR-PFIZER INC-202201170620,PFIZER,,51,YR,,M,Y,,,20220926,,MD,FR,FR,EFAVIRENZ,Pancreatitis acute,213764512,HO,,,213764512,1,201506,201508,,,213764512,1,Oropharyngeal candidiasis
21376989,213769891,1,I,,20220920,20220926,20220926,EXP,,ES-MYLANLABS-2022M1096244,MYLAN,"Gomez AS, Garcia MJA, Maria Rafael Saponi Cortes J, Ruiz CM. Cushing^s syndrome secondary to inhaled fluticasone.. Endocrinol-Diabetes-Nutr. 2022;69(6):442-444",,,,M,Y,,,20220926,,HP,ES,ES,EFAVIRENZ,Cushing's syndrome;Drug ineffective;Drug interaction;Tertiary adrenal insufficiency,213769891,OT,,,213769891,14,,,5,YR,213769891,1,HIV infection
21377221,213772211,1,I,,20220919,20220926,20220926,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK134599,VIIV,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Epiretinal membrane;Eye haemorrhage;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitritis,213772211,OT,,,213772211,1,,,8,WK,213772211,1,HIV infection
21377222,213772221,1,I,,20220919,20220926,20220926,EXP,,CN-GSK-CN2022GSK134599,GLAXOSMITHKLINE,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Epiretinal membrane;Eye haemorrhage;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitritis,213772221,OT,,,213772221,1,,,8,WK,213772221,1,HIV infection
21377271,213772711,1,I,,20220919,20220926,20220926,EXP,,CN-GSK-CN2022GSK136018,GLAXOSMITHKLINE,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitritis,213772711,OT,,,213772711,1,,,4,WK,213772711,1,HIV infection
21377272,213772721,1,I,,20220919,20220926,20220926,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK136019,VIIV,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Eye haemorrhage;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitreous haemorrhage;Vitritis,213772721,OT,,,213772721,1,,,8,WK,213772721,1,HIV infection
21377273,213772731,1,I,,20220919,20220926,20220926,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK136018,VIIV,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitritis,213772731,OT,,,213772731,1,,,4,WK,213772731,1,HIV infection
21377274,213772741,1,I,,20220919,20220926,20220926,EXP,,CN-GSK-CN2022GSK136019,GLAXOSMITHKLINE,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;9",,,,,Y,,,20220926,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Eye haemorrhage;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vision blurred;Visual acuity reduced;Vitreous haemorrhage;Vitritis,213772741,OT,,,213772741,1,,,8,WK,213772741,1,HIV infection
21378124,213781241,1,I,,20220914,20220926,20220926,EXP,,IT-CIPLA LTD.-2022IT05586,CIPLA,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al.. Alzheimer Dementia in People Living With HIV.. Neurol-Clin-Pract. 2021;11 (5):E627 to E633",71,YR,,M,Y,,,20220927,,HP,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,213781241,OT,,,,,,,,,213781241,1,HIV infection
21380740,213807401,1,I,,20220920,20220927,20220927,EXP,,US-MYLANLABS-2022M1096775,MYLAN,"Barnett SK, Armas-Kolostroubis L, Sension M, Riedel DJ. Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient. AIDS 2022;36(10):1475-1476.",,,A,F,Y,,,20220927,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal disorder;Treatment failure,213807401,OT,,,213807401,1,,,94,MON,213807401,1,HIV infection
21381549,213815491,1,I,,20220922,20220927,20220927,EXP,,GB-ABBVIE-4130066,ABBVIE,,3,MON,,M,Y,,,20220927,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen abnormal,213815491,CA,,,,,,,,,213815491,1,Maternal exposure timing unspecified
21383905,213839051,1,I,20150101,20220915,20220928,20220928,EXP,,PT-AUROBINDO-AUR-APL-2022-037937,AUROBINDO,,45,YR,,M,Y,,,20220928,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213839051,OT,,,213839051,1,200307,201504,,,213839051,1,Antiretroviral therapy
21387525,213875251,1,I,,20220913,20220928,20220928,EXP,,CA-JNJFOC-20220953572,JOHNSON AND JOHNSON,,,,,,Y,,,20220928,,MD,CA,CA,EFAVIRENZ,Amylase increased;Blood cholesterol increased;Low density lipoprotein;Neutropenia,213875251,OT,,,213875251,1,2014,,,,213875251,1,HIV infection
21388465,213884651,1,I,,20220926,20220928,20220928,EXP,,CA-BAUSCH-BL-2022-022626,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220928,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,213884651,DE,,,,,,,,,213884651,1,Bipolar disorder
21390191,213901911,1,I,20150101,20220919,20220929,20220929,EXP,,PT-009507513-2209PRT006906,MERCK,,45,YR,,M,Y,,,20220929,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,213901911,OT,,,213901911,1,201505,201511,,,213901911,1,Antiretroviral therapy
21390251,213902511,1,I,,20220926,20220929,20220929,EXP,,CA-AstraZeneca-2022A330116,ASTRAZENECA,,54,YR,,M,Y,,,20220929,,MD,CA,,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,213902511,OT,,,,,,,,,213902511,1,HIV infection
21391532,213915321,1,I,,20220926,20220929,20220929,EXP,,CN-GILEAD-2022-0599382,GILEAD,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X, Lu H, Wang Z. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;unk:unk. doi:10.3389/fmed.2022.807013",50,YR,A,M,Y,,,20220929,,HP,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,213915321,OT,,,,,,,,,213915321,1,HIV infection
21391585,213915851,1,I,,20220926,20220929,20220929,EXP,,CN-GILEAD-2022-0599385,GILEAD,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X, Lu H, Wang Z.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series. Frontiers in Medicine. 2022;unk:unk. doi:10.3389/fmed.2022.807013",40,YR,A,M,Y,,,20220929,,HP,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,213915851,OT,,,,,,,,,213915851,1,HIV infection
21393961,213939611,1,I,,20220919,20220930,20220930,EXP,,CA-AUROBINDO-AUR-APL-2022-039689,AUROBINDO,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: A report of four cases.. AIDS. 2008;22(14)",54,YR,,M,Y,,,20220930,,HP,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,213939611,OT,,,,,,,,,213939611,1,Depression
21395027,213950271,1,I,,20220919,20220930,20220930,EXP,,CA-AUROBINDO-AUR-APL-2022-039545,AUROBINDO,,54,YR,,M,Y,,,20220930,,HP,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,213950271,OT,,,,,,,,,213950271,1,Depression
21395959,213959591,1,I,20120521,20180819,20220930,20220930,EXP,,NVSC2018GB021924,NOVARTIS,,43,YR,,F,Y,,,20220930,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,213959591,CA,,,213959591,2,20100610,20180205,4,MON,213959591,1,Product used for unknown indication
6753908,675390816,16,F,20060602,20220914,20080911,20220920,EXP,,CA-MERCK-0809CAN00002,MERCK,"Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-2",44,YR,,M,Y,,,20220920,,MD,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,675390816,HO,,,675390816,1,20070626,20070626,2,DAY,675390816,1,HIV infection
6870587,687058710,10,F,20060602,20220914,20081231,20220926,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14457303,BRISTOL MYERS SQUIBB,"Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008; 22(14): 1890-2. 10.1097/QAD.0b013e32830e0169",44,YR,A,M,Y,,,20220926,,MD,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,687058710,HO,,,687058710,2,20060602,20070522,355,DAY,687058710,1,HIV infection
6870591,68705915,5,F,,20220810,20081231,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14455729,BRISTOL MYERS SQUIBB,"Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008;22(14):1890-2.",54,YR,A,M,Y,,,20220823,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression;Depression suicidal;Drug interaction;Loss of personal independence in daily activities;Off label use;Paranoia;Prescribed overdose;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation,68705915,DE,,,68705915,4,2004,,,,68705915,1,Bipolar disorder
7057071,70570716,6,F,,20220914,20090722,20220922,EXP,,CA-JNJFOC-20090704890,JOHNSON AND JOHNSON,,52,YR,A,M,Y,,,20220922,,MD,CA,CA,EFAVIRENZ,Progressive external ophthalmoplegia,70570716,OT,,,70570716,3,200802,,106,MON,70570716,1,HIV infection
7302622,730262241,41,F,,20220810,20100302,20220812,EXP,,CA-MERCK-0907CAN00093,MERCK,"Pfeffer G, Mezei MM, Montaner JS, Li CC, Jitratkosol M, Cote HC. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. NEUROLOGY. 2009;73(1):71-2",52,YR,,M,Y,,,20220812,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,730262241,OT,,,730262241,1,200802,200802,91,DAY,730262241,1,HIV infection
7609977,760997727,27,F,20061128,20220704,20100928,20220712,EXP,,JP-JNJFOC-20100907113,JOHNSON AND JOHNSON,,49,YR,A,M,Y,,,20220712,,MD,JP,JP,EFAVIRENZ,Anaemia;Dyslipidaemia;Hepatocellular carcinoma;Hyperbilirubinaemia;Osteoporosis;Pyelonephritis,760997727,HO,,,760997727,1,20061111,19970924,280,DAY,760997727,1,HIV infection
